

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problems Mailbox.**

**THIS PAGE BLANK (USPTO)**

---

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



7009W0

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C07H 21/04, C12N 1/00, 5/00, 5/10, 15/00, 15/09, 15/11, 15/12, C12P 21/06</b>		<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 98/45313</b>
			<b>(43) International Publication Date:</b> 15 October 1998 (15.10.98)
<b>(21) International Application Number:</b> PCT/US98/05892			<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
<b>(22) International Filing Date:</b> 25 March 1998 (25.03.98)			
<b>(30) Priority Data:</b> 60/043,407 4 April 1997 (04.04.97) US 60/046,154 8 May 1997 (08.05.97) US			
<b>(71) Applicant (for all designated States except US):</b> AMYLIN PHARMACEUTICALS, INC. [US/US]; 9373 Towne Centre Drive, San Diego, CA 92121 (US).			
<b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> LARKIN, Sarah [IE/US]; 2005 Ebers Street, San Diego, CA 92017 (US). MOORE, Candace [US/US]; 8866 Pipestone Way, San Diego, CA 92129 (US). ALBRANDT, Keith [US/US]; 5024 Via Playa Los Santos, San Diego, CA 92124 (US). YOUNG, Andrew [NZ/US]; 9514 Easter Way, San Diego, CA 92121 (US). BEAUMONT, Kevin [US/US]; 10872 Pinot Noir Circle, San Diego, CA 92131 (US).			
<b>(74) Agents:</b> DUFT, Bradford, J. et al.; Lyon & Lyon LLP, Suite 4700, 633 West Fifth Street, Los Angeles, CA 90071 (US).			<b>Published</b> With international search report.
<b>(54) Title:</b> NOVEL UNCOUPLING PROTEIN AND METHODS OF USE			
<b>(57) Abstract</b> <p>A novel uncoupling protein, which we have designated UCP-3, that is expressed in skeletal muscle and brown adipose tissue (BAT), and nucleic acid molecules which encode for said novel protein, are described. Methods of screening for compounds that regulate the expression and the activity of UCP-3 are described, as well as methods of treating diseases or conditions in which the regulation of thermogenesis or respiratory ATP synthesis is desired. Such conditions include obesity, diabetes, malignant hyperthermia, and fever. The construction of cell lines that express UCP-3 is also described.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		



## DESCRIPTION

### NOVEL UNCOUPLING PROTEIN AND METHODS OF USE

#### Field of the Invention

A novel uncoupling protein, which we have designated UCP-3, that is expressed in skeletal muscle and brown adipose tissue (BAT), and nucleic acid molecules which encode said  
5 novel protein, are described. Methods of screening for compounds that regulate the expression and the activity of UCP-3 are described, as well as methods of treating diseases or conditions in which the regulation of thermogenesis, or  
10 respiratory ATP synthesis, is desired. Such conditions include obesity, diabetes, malignant hyperthermia, and fever. The construction of cell lines that express UCP-3 is also described.

#### Background

15       Uncoupling Protein (UCP; thermogenin) is a proton-translocating protein present in the inner mitochondrial membrane of brown adipose tissue, a specialized tissue which functions in heat generation and energy balance (Nicolls, D.G., and Locke, R.M., *Physiol. Rev.* 64:2-40 (1984);  
20 Rothwell, N.J. and Stock, M.J., *Nature*, 281:31-35 (1979)). Mitochondrial oxidation of substrates, such as pyruvate and fatty acids, is accompanied by proton transport out of the mitochondrial matrix, creating a transmembrane proton  
25       gradient. Re-entry of protons into the matrix via ATP synthase is coupled to ATP synthesis. However, in brown

adipose tissue mitochondria, UCP functions as a transmembrane proton transporter, permitting re-entry of protons into the mitochondrial matrix unaccompanied by ATP synthesis, resulting in heat release and an increase in the rate of respiration. Environmental exposure to cold evokes neural and hormonal stimulation of brown adipose tissue, which increases UCP mediated proton transport, brown fat metabolic activity, and heat production. (Susulic, V.S., and Lowell, B.B., Curr. Opin. In Endocrinol. and Metab. 3:44-50 (1996); Himms-Hagen, J., Brown adipose tissue metabolism, in Obesity (Bjorntorp, P. and Brodoff, B.N., eds., 1993) pp. 15-34.)

Recent studies with transgenic models indicate that brown fat and UCP have an important role in energy expenditure in rodents. Transgenic mice in which brown adipocyte tissue was ablated by a toxin coupled to the UCP-promoter developed both obesity and diabetes (Lowell, B.B., et al., Nature 366:740 (1993)). The development of obesity in these transgenic animals appeared to be of metabolic origin because hyperphagia was absent, suggesting that the uncoupled mitochondrial respiration of brown fat is an important component of energy expenditure. In a separate transgenic mouse model, ectopic expression of UCP in white adipose tissue of genetically-obese mice led to a significant reduction in body weight and fat stores (Kopecky J., et al, J. Clin. Invest. 96:2914-23 (1995)). These studies indicate that activity of UCP is accompanied by energy expenditure and weight loss in rodents. (Id.)

In humans, brown fat deposits are present in infants but regress in size in adults. However, brown adipose tissue can be reactivated in pathological conditions, such as pheochromocytoma and alcoholism (Lean, M.E.J., Obesity 117-29

(1992)). Also, mRNA coding for UCP is present in omental and subcutaneous white fat deposits, suggesting that brown adipocytes may be dispersed within these fat deposits (Krief, S. et al., J. Clin. Invest., 91:344-49, (1993)). The role, if any, of brown adipose tissue in non-shivering thermogenesis and energy metabolism in adult humans has yet to be demonstrated. (Lean, M.E.J., Evidence for brown adipose tissue in humans, in Obesity (Bjorntorp, P. and Brodoff, B.N., eds. 1993) pp. 117-129; Susulic, V.S., and Lowell, B.B., Curr. Opin. in Endocrinol. and Metab. 3:44-50 (1996)).

A human cDNA that encodes a UCP-related protein that is enriched in tissues of the lymphoid lineage has been cloned (Fleury, C. et al., Nature Genetics, p.15 (March 1997) (GenBank Accession Number 476367); Boxx, O. et al., GenBank Accession Number U82819). A similar human UCP-related sequence has been cloned and various tissues analyzed for its expression; this UCP-related sequence was found to be expressed in heart, placental, lung, liver, muscle, kidney and pancreatic tissue (PCT application number PCT/US95/10918, published as WO 96/05861). Because of this data, and the description presented herein, UCP is henceforth designated UCP-1 for purposes of this description; the above-referenced UCP-related protein (Fleury et al.) is designated UCP-2.

Thermogenic protein activity, such as that found with UCP-1, may be useful in reducing, or preventing the development of excess adipose tissue, such as that found in obesity. Obesity is becoming increasingly prevalent in developed societies. For example, approximately 30% of adults in the U.S. were estimated to be 20 percent above desirable body weight--an accepted measure of obesity

sufficient to impact a health risk. (*Harrison's Principles of Internal Medicine* 12th Edition, McGraw Hill, Inc. (1991) p. 411). The pathogenesis of obesity is believed to be multifactorial, but the basic problem is that in obese subjects food intake and energy expenditure do not come into balance until there is excess adipose tissue. Attempts to reduce food intake, or to decrease hypernutrition, are usually fruitless in the medium term because the weight loss induced by dieting results in both increased appetite and decreased energy expenditure. (Leibel et al., (1995) *New England Journal of Medicine* 322:621-28). The intensity of physical exercise required to expend enough energy to materially lose adipose mass is too great for many obese people to undertake on a sufficiently frequent basis. Thus, obesity is currently a poorly treatable, chronic, essentially intractable metabolic disorder. In addition obesity carries a serious risk of co-morbidities including, Type 2 diabetes, increased cardiac risk, hypertension, atherosclerosis, degenerative arthritis, and increased incidence of complications of surgery involving general anesthesia. An increased level in thermogenesis in obese individuals, or individuals with a predisposition toward obesity should help to reduce the level of adipose tissue, and therefore avoid the complications associated with obesity.

Too high of a level of thermogenesis may also be detrimental for certain individuals, thus a method of decreasing the level of thermogenesis in such individuals is desirable. It would be desirable, for example, to treat or prevent conditions such as malignant hyperthermia, which occurs in approximately 1 in 50,000 anesthetic procedures, and can have about a 70% mortality rate. Studies in pigs,

which are susceptible to malignant hyperthermia, have suggested that it may be caused by inappropriate activation of a sarcoplasmic reticulum Ca<sup>+</sup> release channel (the ryanodine receptor) which then acts in a positive feedback manner to further release intracellular calcium and, thus affecting myotonic contraction and thermal overload (Mickelson, J.R., and Louis, C.F., Physiol. Rev. 76:537-92 (1996)). However, defects in the ryanodine receptor are found in only approximately 50% of patients with malignant hyperthermia (MacLennan, D.H., Curr. Opin. Neurol. 8:397-401 (1995)). There is discord between actual incidence and predicted genetic susceptibility based upon detection of mutant ryanodine receptors in some, but not all humans with malignant hyperthermia (MacLennan, D.H., Curr. Opin. Neurol., 8:397-401 (1995)). Four chromosomal loci linked to malignant hyperthermia have been identified in familial studies, but for only one has the genetic defect been localized to mutations of a particular gene, the ryanodine calcium channel gene on chromosome 19 (Id.; Steinfath, M., et al., Anesthesiol. Intensivmed Notfallmed Schmerzther 31:334-43 (1996)). It would therefore be useful to identify the protein involved in human malignant hyperthermia, and to design methods of regulating its expression to prevent or treat malignant hyperthermia.

Another condition where thermogenesis is increased is in fever, an increase in body temperature in response to infection or inflammation. Fever is observed not only in mammals and birds (warm-blooded animals; homeotherms), but also in some poikilothermic (cold-blooded) animals such as lizards, which increase their temperature behaviorally, by seeking warmer surroundings. Inoculated poikilothermic

animals that are denied access to a warmer environment have a higher mortality, supporting a general advantage of being able to increase body temperature during infection. The mechanism underlying this advantage has been elusive, but may  
5 involve changes in properties of iron-binding proteins, resulting in a drop of free-iron in body fluids, to which bacteria are particularly susceptible.

However, there are clinical settings in which fever is dangerous or unpleasant. These include epileptic patients  
10 where fever may precipitate convulsions; elderly patients with cardiac or cerebrovascular disease; children, who are at risk for febrile convulsions (which may then predispose to later epilepsy); patients with hyponutrition and chronic fever, where the increased metabolic demand of maintaining a  
15 higher body temperature compromises body energy stores; patients with fluid balance disturbances where the sweating associated with rapid up and down resetting of body temperature can exacerbate salt loss and electrolyte disturbance.

20 As opposed to the unregulated heat gain in malignant hyperthermia, exercise and heat-stroke, heat gain in fever is a regulated event that recruits all of those mechanisms that are employed in normal autonomic and behavioral thermoregulation. From a control system perspective, there  
25 is a shift in body temperature set-point so that a higher body temperature is defended. Effector systems used to defend the higher body temperature in fever (shivering, non-shivering UCP-mediated thermogenesis, vasoconstriction, piloerection, warmth-seeking behaviors, heat-loss-lessening  
30 behaviors) are the same responses that are observed during cold exposure in non-febrile circumstances. Compounds that

defeat one or more of these effector responses will be useful to reduce fever.

Thus there is a need for the identification of genes that code for proteins that are implicated in thermogenesis. Methods of regulating such gene expression, and such protein activity, will be useful in regulating thermogenesis.

#### SUMMARY OF THE INVENTION

The present invention concerns a novel uncoupling protein, which we have designated UCP-3, that is expressed in skeletal muscle and brown adipose tissue (BAT), isolated nucleic acid molecules that encode UCP-3, as well as methods of screening for compounds that regulate the expression and/or the activity of UCP-3. Compounds that regulate the activity of UCP-3 will regulate thermogenesis, respiratory ATP synthesis, and energy utilization in skeletal muscle and BAT, and will be useful in treating or preventing diseases or conditions in which regulation of thermogenesis will be beneficial. Such conditions include, but are not limited to, obesity, diabetes, malignant hyperthermia, and fever.

Thus, one embodiment of the invention comprises isolated nucleic acid molecules which encode UCP-3. The encoded UCP-3 may be the UCP-3 sequence encoded in any eukaryotic cell, preferably a vertebrate cell, more preferably a mammalian cell. In one preferred aspect, the invention provides an isolated nucleic acid molecule which encodes rat UCP-3. In another preferred aspect is an isolated nucleic acid molecule which encodes mouse UCP-3. Especially preferred are nucleic acid molecules which encode human UCP-3. In more preferred aspects, said nucleic acid encodes an amino acid sequence comprising the amino acid sequence of Figure 5. In most

preferred aspects, said nucleic acid molecule comprises the nucleic acid sequence of Figure 5. The term "UCP-3" includes, but is not limited to, all isoforms thereof, generated by alternative splicing of the primary transcript  
5 that gives rise to a nucleotide sequence that encodes the amino acid sequence shown in Figure 5.

In another embodiment of the present invention, a nucleic acid molecule encoding UCP-3 is operably linked to a promoter sequence, wherein said promoter sequence promotes  
10 the transcription of the coding region of said nucleic acid.

Also provided in the present invention, are vectors comprising a nucleic acid molecule of the present invention. In preferred aspects, said vectors further comprise a promoter sequence which is operably linked to said nucleic  
15 said molecule. In more preferred embodiments, said vectors further comprise a 3' polyadenylation sequence which is operably linked to said nucleic acid molecule. Also within the scope of the present invention are host cells transformed with the nucleic acid molecules or vectors of the present  
20 invention.

In another embodiment of the invention, isolated UCP-3 is provided. The UCP-3 may be, for example, isolated from a cell that comprises an endogenous nucleic acid molecule that encodes UCP-3. The UCP-3 may be isolated from a cell that  
25 expresses UCP-3 from a heterologous nucleic acid molecule, such as in a transformed cell. The cell may be eukaryotic or prokaryotic. Alternatively, UCP-3 may be synthesized by methods known to those skilled in the art, including, but not limited to UCP-3 that is expressed in, and/or isolated from a  
30 cell-free translation system, or isolated through chemical synthesis.



In another embodiment of the present invention anti-UCP-3 antibodies are provided. Preferably these antibodies bind to an amino acid sequence that is not completely homologous among all three UCPs. More preferably these  
5 antibodies bind to a region comprising amino acids 47-60, or amino acids 303-313 of said UCP-3 sequence. More preferably, the anti-UCP-3 antibody is a monoclonal antibody.

In yet other embodiments of the present invention are provided methods of gene therapy comprising administering to  
10 a subject a nucleic acid molecule that encodes UCP-3. In one preferred aspect is provided a method of increasing thermogenesis in a subject, comprising administering to said subject a nucleic acid molecule which encodes UCP-3, wherein said administering of said nucleic acid molecule increases  
15 the level of UCP-3 expression in one or more tissues of said subject. Preferably, said tissue is skeletal muscle tissue. More preferably said tissue is adipose tissue. Most preferably, said tissue is white adipose tissue. Said method is preferably for purposes of treating obesity, and/or  
20 decreasing fat in a subject. Other methods of gene therapy provided in the present invention are methods for decreasing expression of UCP-3 in a subject by administering to said subject an antisense nucleic acid molecule wherein said administering of said nucleic acid molecule decreases the  
25 level of UCP-3 expression in one or more tissues of said subject. Preferably said method is used for decreasing malignant hyperthermia, or fever, in said subject. Preferably said tissue is skeletal muscle tissue.

Another embodiment of the invention comprises a method  
30 of screening for a compound that binds to or modulates the activity of UCP-3, comprising

a) introducing said UCP-3 and one or more test compounds into an acceptable medium, and  
b) monitoring the binding or modulation by physically detectable means,

5 c) thereby identifying those compounds that bind to or modulate the activity of said UCP-3.

In one preferred aspect, UCP-3 is associated with a mitochondrial membrane. In another preferred aspect, said monitoring of the binding or modulation of said compound to  
10 UCP-3 further comprises monitoring the level of purine nucleotide binding of UCP-3 in the presence of said compound or compounds; and identifying the compounds that, when in the presence of UCP-3, alter the level of purine nucleotide binding to UCP-3. Preferably, said purine nucleotide is GDP.  
15 In other preferred aspects, the method further comprises monitoring the level of purine nucleotide binding of UCP-3 in the absence of said compound or compounds.

In another preferred aspect of the invention, said monitoring of the binding to or modulation of UCP-3 by said  
20 compound further comprises monitoring the level of fatty acid binding of UCP-3 in the presence of said compound; and identifying the compounds that, when in the presence of UCP-3, alter the level of fatty acid binding to UCP-3.  
Preferably, said fatty acid is laurate. In other preferred  
25 aspects, said monitoring further comprises monitoring the level of fatty acid binding of UCP-3 in the absence of said compound.

In another preferred embodiment of the invention, a method is provided for screening for a compound that binds to  
30 or modulates the activity of UCP-3, comprising monitoring the effect of said compound on a cell that expresses UCP-3.

In one preferred aspect, the cell that expresses UCP-3 is present in skeletal muscle tissue. In another aspect, the cell that expresses UCP-3 is present in brown adipose tissue. Preferably, the cell that expresses UCP-3 is transformed with a nucleic acid encoding UCP-3. The nucleic acid may preferably be operably limited to the UCP-3 native promoter, or to a heterologous promoter. By "heterologous promoter" is meant any promoter that allows the expression of UCP-3, that is not the endogenous UCP-3 promoter. More preferably, the nucleic acid encodes an amino acid sequence comprising the amino acid sequence of Figure 5.

In another preferred embodiment, the nucleic acid comprises the nucleic acid sequence of Figure 5. In another preferred embodiment, the method further comprises monitoring the effect of said compound on a cell that does not express UCP-3. Preferably, said cell that does not express UCP-3 is otherwise substantially genetically identical to said cell that expresses UCP-3.

One preferred method of monitoring of the effect of said compound on said cell comprises monitoring the level of mitochondrial respiration of said cell. Other preferred methods comprise monitoring the level of mitochondrial respiration in isolated mitochondria. Most preferred methods comprise monitoring the level of mitochondrial respiration or whole animals, preferably mammals, more preferably rats or mice, and most preferably humans. In another preferred method, the monitoring of the effect of said compound on said cell comprises monitoring the level of mitochondrial membrane purine nucleotide binding, preferably GDP, of said cell.

In another preferred method, said monitoring of the effect of said compound on said cell comprising monitoring

the level of fatty acid, preferably laurate.

In preferred embodiments, said UCP-3 of the present invention, and used in the methods of the present invention, as well as UCP-3 encoded by the nucleic acids used in the methods of present invention, is human UCP-3. Preferably, said UCP-3 comprises the amino acid sequence of Figure 5. Most preferably, said UCP-3 is encoded by a nucleic acid molecule comprising the nucleic acid sequence of Figure 5. The term "UCP-3" also includes the various isoforms of UCP-3 due to variations in the splicing of the RNA transcript coding for UCP-3. UCP-3s that contain post-translational modifications that are required for activity or modulate activity are also within the scope of the present invention.

The compound that regulates UCP-3 activity may be found to either activate or decrease UCP-3 activity.

In another preferred embodiment, a method is provided for screening for a compound that regulates the expression of UCP-3, comprising monitoring the effect of said compound on the level of expression of UCP-3 RNA in a cell that expresses UCP-3. Preferably, the cell that expresses UCP-3 is present in skeletal muscle tissue. The cell may also be present in brown adipose tissue. Preferably, the cell that expresses UCP-3 is transformed with a nucleic acid encoding UCP-3.

More preferably, said nucleic acid encodes an amino acid sequence comprising the amino acid sequence of Figure 5. Most preferably, the nucleic acid comprises the nucleic acid sequence of Figure 5. In another preferred aspect, the method utilizes a yeast cell that is transformed with a nucleic acid that encodes UCP-3. In more preferred aspects, said cell is a transformed eukaryotic cell, preferably a vertebrate cell, more preferably a mammalian cell, such as

those known to those of skill in the art, and those described herein. In other preferred aspects, said cell is a transformed yeast cell. Preferably, the methods involve determining whether the expression of said messenger RNA is increased or decreased compared to the expression of said messenger RNA in a cell that has not been exposed to said compound. Preferably, said UCP-3 is human UCP-3. More preferably, said UCP-3 is encoded by a nucleic acid sequence comprising the nucleic acid sequence of Figure 5.

10 In one preferred aspect, the level of UCP-3 RNA is determined by probing the messenger RNA expressed in said cell with a nucleotide probe that comprises a nucleotide sequence that is homologous to at least 15, preferably 30, more preferably 45, consecutive nucleotides of a UCP-3  
15 nucleotide sequence. Preferably, said nucleotide probe does not substantially bind under high stringency conditions to any non-UCP-3 nucleotide sequence in the same tissue. By "high stringency hybridization conditions" is meant those hybridizing conditions that (1) employ low ionic strength and  
20 high temperature for washing, for example, 0.015 M NaCl/0.0015 M sodium citrate/0.1% SDS at 50°C; (2) employ during hybridization a denaturing agent such as formamide, for example, 50% (vol/vol) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium  
25 phosphate buffer at pH 6.5 with 750 mM NaCl, 75 mM sodium citrate at 42°C; or (3) employ 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M Sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 g/ml), 0.1% SDS, and 10% dextran sulfate at 42°C, with washes at 42°C in 0.2 x SSC and  
30 0.1% SDS. Under stringent hybridization conditions only highly complementary nucleic acid sequences hybridize.

Preferably, such conditions prevent hybridization of nucleic acids having 1 or 2 mismatches out of 20 contiguous nucleotides binding of said cell.

In other methods of the present invention, the effect of  
5 a compound on the level of expression of UCP-3 is further monitored on a cell that does not express UCP-3 thus, providing a negative control.

Preferably, said cell that does not express UCP-3 is otherwise substantially genetically identical to said cell  
10 that expresses UCP-3.

The compound may either increase or decrease the expression of UCP-3. In other aspects, the compound may bind to a transcriptional regulatory sequence that increases or decreases the expression of UCP-3 RNA.

15 In another embodiment of the invention is provided a method for treating conditions or disorders that can be ameliorated by increasing the level of thermogenesis in a subject, for example obesity, comprising administering to said subject a therapeutically effective amount of a compound  
20 that increases the activity of UCP-3. In one aspect, said condition or disorder is obesity. By condition or disorder is meant a disease, condition, or disorder, or a susceptibility to the same.

In another embodiment of the invention is provided a  
25 method for treating conditions or disorders that can be ameliorated by decreasing the level of thermogenesis in a subject, for example, in a subject with a susceptibility to malignant hyperthermia, or fever, comprising administering to said subject a therapeutically effective amount of a compound  
30 that decreases the activity of UCP-3.

Also provided within the scope of the present invention

is a method of preventing or treating diseases or conditions related to a decrease in thermogenesis, such as obesity, in a subject comprising administering to said subject a therapeutically effective amount of a compound that increases UCP-3 activity in said subject. Preferably, said UCP-3 activation occurs in a tissue, preferably the skeletal muscle tissue of said subject. Said increase in UCP-3 activity may be associated with, for example, an increase in UCP-3 activation. Said compound may the alter post-translational modification of UCP-3. Alternatively, said increase in UCP-3 activity is associated with an increase in UCP-3 gene expression.

A method is also provided of preventing or treating diseases or conditions related to thermogenesis such as malignant hyperthermia or fever in a subject comprising administering to said subject a therapeutically effective amount of a compound that decreases the activity of UCP-3 in muscle tissue. Preferably, said decrease in UCP-3 activity is associated with an increase in UCP-3 activation. Said compound may alter the post-translational modification of UCP-3. Alternatively, said decrease in UCP-3 activity is associated with a decrease in UCP-3 gene expression.

Diagnostic methods are also provided in the present invention. In one embodiment, a method is provided for determining whether a subject has a susceptibility to a condition or disorder related to thermogenesis, such as, for example, malignant hyperthermia or obesity, comprising: probing the messenger RNA expressed in a tissue of said subject with a nucleotide probe that comprises a nucleotide sequence that is homologous to at least 15, preferably at least 30, more preferably at least 45, consecutive

A method is also provided for determining whether a subject has a condition or disorder related to a defect in the expression level of UCP-3 in a tissue of said subject comprising determining the level of UCP-3 present in said tissue and comparing said level of UCP-3 with the level of UCP-3 in a subject that does not have a condition or disorder related to a defect in the expression level of UCP-3. In a preferred aspect, said level of UCP-3 present in said tissue is determined by probing said tissue with an antibody, preferably a monoclonal antibody, that recognizes UCP-3.

16



obesity said subject is determined to have a susceptibility to hyperthermia if said defect in the expression level of UCP-3 in said tissue of said subject results in an increased level of UCP-3 as compared to a subject that does not have a susceptibility to hyperthermia. In other preferred aspects, said subject may be determined to have a condition or disorder related to thermogenesis if said subject is found to have one or more deletions or point mutations in the UCP-3 gene. Said deletion or mutation may or may not affect the expression level of UCP-3 RNA, but may affect the activity of UCP-3.

#### Brief Description of the Drawings

Figure 1: Nucleotide (SEQ ID NO. 1) and deduced amino acid (SEQ ID NO. 2) sequence of the carboxy terminal fragment of human UCP-3. The nucleotide numbering scheme is presented along the right margin. The sixth transmembrane domain (Klingenberg, M., Trends Biochem Sci. 15:108-12 (1990)) is indicated by a horizontal line over the sequence. The putative purine nucleotide recognition element (Murdza-Inglis, D.L., et al., J. Biol. Chem. 269:7435-38 (1994)) is boxed. The deduced amino acid sequence is shown below the nucleotide sequence. The standard one letter abbreviations for amino acids are used: A, alanine; C, cysteine; D, aspartic acid; E, glutamic acid; F, phenylalanine; G, glycine; H, histidine; I, isoleucine; K, lysine; L, leucine; M, methionine; N, asparagine; P, proline; Q, glutamine; R, arginine; S, serine; T, threonine; V, valine; W, tryptophan; Y, tyrosine.

Figure 2. Alignment of portions of the human UCP-1 and UCP-3 sequences. Amino acid identities are shown. The

numbering of the amino acids for each protein is shown in the right margin. The sixth transmembrane domain (Klingenberg, M., *Trends Biochem Sci.* 15:108-12 (1990)) is indicated by a horizontal line over the sequence. The putative purine nucleotide recognition element is boxed (Murdza-Inglis, D.L., et al., *J. Biol. Chem.* 269:7435-38 (1994); Bouillaud, F., et al., *EMBO J.* 13:1990-97 (1994)). The sequence of human UCP-1 was deduced from GenBank accession number U28480.

Figure 3: Tissue distribution of transcripts for human UCP-3. Northern analysis is shown of poly (A)<sup>+</sup> RNA from (A) human tissues and (B) rat tissues hybridized with a UCP-3-specific probe and washed at high stringency (0.1 XSSC, 0.1%SDS, 60°C). Abbreviations: HRT, heart; BRN, brain; PLA, placenta; SPL, spleen; LUN, lung; LIV, liver; SKM, skeletal muscle; KID, kidney; PAN, pancreas; TST, testes. Dashes to the left of each panel indicate the relative migration of RNA size markers 9.49, 7.46, 4.40, 2.37, and 1.35 kilobases.

Figure 4: In vivo regulation of UCP-3 by cold and triiodothyronine (T3) treatment. Northern analysis is shown of RNA extracted from skeletal muscle (SKM), heart (HRT), white fat (WAT) and brown fat (BAT) of rats treated as follows: maintained at normal room temperature with no drug treatment ("control"), maintained at room temperature and treated with 3.3 µg/ml T3 in their drinking water, or maintained at 4°C ("cold acclimatized").

Figure 5: Nucleotide sequence (SEQ ID NO. 3) and deduced amino acid sequence (SEQ ID NO. 4) of human UCP-3. The nucleotide numbering scheme is presented along the right margin and the amino acid numbering scheme is presented along the left margin. The deduced amino acid sequence is shown below the nucleotide sequence. The six transmembrane domains

are indicated by horizontal lines (Klingenberg, 1990). The putative purine nucleotide recognition element is boxed (Murdza-Inglis et al., 1994; Bouillaud et al., 1994). Note that the last 25 nucleotides (positions 971-995) are contributed by the A850 primer used for amplification. The standard one letter abbreviations for amino acids are used, as described in the legend for Figure 1.

Figure 6: Alignment of human UCP-1 (top), UCP-2 (middle), and UCP-3 (bottom). Identities between all three proteins are shaded in black and those between any two proteins are shaded in gray. The numbering of the amino acids for each protein is shown in the left margin. The sixth transmembrane domain (Klingenberg, 1990) is indicated by a horizontal line over the sequence. The putative purine nucleotide recognition element is boxed (Murdza-Inglis et al., 1994; Bouillaud et al., 1994). The sequence of human UCP-1 was deduced from GenBank accession number U28480 and that of human UCP-2 was determined by Applicants. The human UCP-2 sequence shown differs from the sequence in GenBank Accession Number 476367 at amino acid 219, at which position the sequence in Accession Number 476367 indicates an isoleucine residue and the Applicants' sequence indicates a threonine residue. The alignment was rendered by the Megalign program from the Lasergene suite of biocomputing software (DNASTAR, Inc., Madison, WI) (Higgins, D.G. and Sharp, P.M., CABIQS, Vol. 5, No. 2, 151-153, 1989).

#### Detailed Description of the Invention

It has now been demonstrated that a novel uncoupling protein is present in skeletal muscle and in BAT. This uncoupling protein, UCP-3, may be used to screen for

compounds that regulate the activity of UCP-3. Such compounds are likely to stimulate fat oxidation, energy expenditure, and weight loss.

The identification, characterization, and cloning of UCP-3 is presented in Example 1. Example 2, which explores the tissue specificity of human UCP-3 expression, indicates that UCP-3 is expressed in skeletal muscle and BAT. Northern analysis of rat tissues indicates that UCP-3 has a highly restricted pattern of expression being detectable only in skeletal muscle and in BAT. Among the adult human tissue extracts tested for this analysis, UCP-3 mRNA was present only in skeletal muscle. Although BAT was not tested for this Northern analysis, it was tested in the analysis of tissue exposed to cold or thyroid hormone. Notably UCP-3 was upregulated in the skeletal muscle of rats exposed to cold or thyroid hormone treatment, although the expression in BAT appears to be unchanged under these conditions. This pattern of expression indicates that UCP-3 is likely to be involved in energy homeostasis and heat regulation even in adult humans that have minimal residual brown fat depots. Compounds that enhance the activity of UCP-3 will stimulate thermogenesis and energy utilization in skeletal muscle, and will be useful in treating obesity and diabetes. The sequence of human UCP-3, reported here, may be used in the construction of cell lines expressing this protein. These cell lines will be useful in screening for compounds which regulate the activity or expression of UCP-3, including, but not limited to, human UCP-3.

Example 3 demonstrates that UCP-3 is activated by cold temperatures and by  $T_3$ , indicating an involvement in muscle energy utilization and thermogenesis. Example 4 demonstrates

the use of UCP-3 to screen for compounds that regulate UCP-3 activity.

Uncoupling of respiration in skeletal muscle is a potentially significant means of stimulating energy expenditure, and subsequent weight loss. The sequence  
5 homology of UCP-3 to UCP-1 suggests that UCP-3 may have a similar function to UCP-1 in mediating mitochondrial proton transport. Should UCP-3 function to uncouple mitochondrial respiration, its location in skeletal muscle and  
10 responsiveness to  $T_3$  and cold supports a role in muscle energy utilization and thermogenesis.

As in Example 1, and elsewhere herein, the nucleotide sequence for UCP-3 may be used to, for example, construct cell lines expressing UCP-3, for example, by transfection  
15 with a suitable expression vector encoding UCP-3. The sequence will also be useful for identifying cells containing UCP-3. Cells expressing UCP-3, either by transfection or endogenously, will be useful in screening for compounds which increase mitochondrial respiration mediated by UCP-3. Such  
20 compounds (UCP-3 activators) may be identified by comparing their ability to stimulate respiration or metabolic activity of UCP-3-expressing cells, compared to control cells, which may be untransfected cells of the same genetic background. Alternatively, isolated mitochondrial preparations could be  
25 used to screen for UCP-3 activators, either by measuring stimulation of respiration, or by measuring mitochondrial swelling in a suitable buffer system.

Included in the methods of the present invention are methods of identifying compounds that bind to UCP-3.  
30 Compounds that bind to UCP-3 are likely to be involved in regulating UCP-3 activity. Protein or peptide binding assays

are known to those skilled in the art, and include, but are not limited to, those that measure co-precipitation, co-migration on non-denaturing SDS-PAGE, and co-migration on Western blots. Binding assays are described in, for example, Bennet, J.P. and Yamamura, H. I., Neurotransmitter, hormone, or drug receptor binding methods in Neurotransmitter Receptor Binding pp. 61-89 (Yamamura, H.I., et al., eds. 1985). Studies with UCP-1 suggest an additional method for identifying activators. UCP-mediated transport is inhibited by certain purine nucleotides, notably diphosphate and triphosphate purine nucleotides, especially GDP, which bind to and occupy an inhibitory site on the protein (Murdza-Inglis, D.L., et al., J. Biol. Chem. 269:7435-38 (1994); Bouillaud, F., et al., EMBO J. 13:1990-97 (1994)). Compounds may occupy this site and prevent nucleotide-mediated inhibition of UCP-1 function, and these compounds may be identified by their ability to inhibit radiolabeled purine nucleotide binding to UCP-containing membranes. Because the amino acid sequence homology of UCP-3 to UCP-1 is reasonably well conserved in the nucleotide inhibitory site, and especially in amino acid residues known to be critical for purine nucleotide binding, then UCP-3 activators may be identified by a similar method. By this method, compound libraries are screened for their ability to inhibit radiolabeled nucleotide binding to UCP-3-containing membranes. Lead compounds may be further tested and optimized for their ability to reduce nucleotide-mediated inhibition of UCP-3 function *in vitro*, and to stimulate thermogenesis and weight loss *in vivo* in suitable animal models.

In an additional method for identifying activators, the

fatty acid binding of UCP-3 in the presence or absence of a test compound may be compared. UCP-1 proton transport activity is also regulated by fatty acids. Adrenergic stimulation predominantly via  $\beta 3$  adrenergic receptors on the cell surface results in increased cAMP levels in the cell and thus stimulation of cAMP-dependent protein kinase (PKA). Activated PKA causes increased lipoprotein lipase activity and thus release of free fatty acids. In vitro UCP-1 can function as a fatty acid anion transporter and it is believed that fatty acids stimulate proton transport across the membrane by themselves mediating the transport of protons as UCP-1-bound protonophores (Garlid, K.D., et al., *JBC*, 271:2615-2620 (1996)). The fatty acid binding domain has been localized to the carboxy terminus by site directed mutagenic studies (Gonzalez-Barroso, M.M., et al., *Eur. J. Biochem.*, 239:445-450 (1996)).

The screening methods described herein may employ naturally expressed, cloned, or synthesized UCP-3. UCP-3 derivatives or analogs may also be used in the screening methods described herein. High-throughput screening of chemical libraries using cells stably transfected with UCP-3 may offer a promising approach to identify new lead compounds which are active on UCP-3 (Knopfel et al., *J. Med. Chem.* 38:1417, (1995)). These lead compounds serve as templates for extensive chemical modification studies to further improve potency, and important therapeutic characteristics such as bioavailability.

It will be appreciated by those in the art that there are various methods useful in preparing and isolating nucleic acids that encode UCP-3. Chemical synthesis of the nucleic acid molecules of the invention is preferred. In general,

chemical synthesis of DNA and recombinant DNA isolation techniques are now well known. An extensive discussion embodying a number of commonly used methodologies can be found in Sambrook *et al.*, *Molecular Cloning, A Laboratory Manual, Second Edition*, Volumes 1 to 3, Cold Spring Harbor Laboratory Press 1989). Recombinant methods allow segments of genetic information, DNA, from different organisms, to be joined together outside of the organisms from which the DNA was obtained and this hybrid DNA to be incorporated into a cell that will allow the production of the protein for which the original DNA encodes. Genetic information encoding a protein of the present invention may be obtained from genomic DNA, mRNA (preferably brown adipose tissue or skeletal muscle tissue mRNA), or total tissue RNA (preferably brown adipose tissue total RNA) of an organism by methods well known in the art. Preferred methods of obtaining this genetic information include isolating mRNA from an organism, converting it to its complementary DNA, incorporating the cDNA into an appropriate cloning vector, and identifying the clone which contains the cDNA encoding the desired protein by means of hybridization with appropriate oligonucleotide probes constructed from known or postulated sequences of the protein. Especially preferred methods of obtaining this genetic information include isolating total tissue RNA, preferably adipose tissue or skeletal muscle tissue total RNA, from an organism, converting it to its complementary DNA, and amplifying, detecting and isolating a cDNA sequence encoding the desired protein. The genetic information in the cDNA encoding a protein of the present invention may be ligated into an expression vector, the vector introduced into host cells, and the genetic information expressed as the protein encoded for.



Mixtures of mRNA can be isolated from eukaryotic cells and double-stranded DNA copies of entire genes synthesized which are complementary to the isolated mRNA. mRNA is first reverse-transcribed to form a single-stranded cDNA by an RNA-directed DNA polymerase, e.g., reverse transcriptase. Reverse transcriptase synthesizes DNA in the 5' to 3' direction, utilizes deoxyribonucleoside 5'-triphosphates as precursors, and requires both a template and a primer strand. By a series of additional reactions, double-stranded cDNA is produced and inserted into cloning or expression vectors by any one of many known techniques, which depend at least in part on the vector selected. Expression vectors refer to vectors which are capable of transcribing and translating DNA sequences contained therein, where such sequences are linked to other regulatory sequences capable of effecting their expression. These expression vectors are replicable in the host organisms or systems as either plasmids, bacteriophage, or as an integral part of the chromosomal DNA. Recombinant vectors and methodology are in general well known and suitable for use in host cells over a wide range of prokaryotic and eukaryotic organisms. The cDNA cloning and expression procedures further described below and in the Examples are but some of a wide variety of well established

methods to produce specific sequences and reagents useful in the invention.

One method of preparing the products of the invention includes the steps of constructing a vertebrate cDNA library, preferably a vertebrate adipose or skeletal muscle cDNA library; ligating the cDNA library into a cloning vector; introducing the cloning vector containing the cDNA library into a first host cell; contacting the cDNA molecules of the first host cell with a solution containing a suitable UCP-3 gene hybridization probe; detecting and then isolating a cDNA molecule which hybridizes to the UCP-3 gene hybridization probe; ligating the hybridizing cDNA molecule into an expression vector; transforming a second host cell with the expression vector containing the cDNA molecule which encodes UCP-3; culturing the transformed second host cell under conditions that favor the production of UCP-3, and isolating the UCP-3 expressed by the second host cell.

The nucleic acid molecule products of the invention may also be prepared by the method described in Example 1. The isolated nucleic acid molecules encoding UCP-3 include, but are not limited to, DNA, mRNA, cDNA, and variants which use, for example, preferred codons for expression in various cells or tissues. Such preferred codons are disclosed in, for example, Grantham et al., Nuc. Acids Res., 9:43-74 (1981), and Lathe, J. Mol. Biol., 183:1-12 (1985). These articles, and all other publications referenced herein, are hereby incorporated in their entirety by reference. The modifications can be readily achieved using PCR mutagenesis approaches such as are well known to those skilled in the art.

Preferred natural sources of mRNA from which to

construct a cDNA library are vertebrate adipose tissue, for example, brown adipose tissue, or skeletal muscle tissue. Preferred methods of isolating mRNA encoding a protein of the present invention, along with other mRNA, from an mRNA source  
5 include poly U or poly dT chromatography. Other methods for RNA extraction, include an acid guanidinium thiocyanate procedure whereby adipose or skeletal muscle tissue total RNA and oligonucleotide primers are prepared for use in the isolation and cloning of the UCP-3 gene, as is known in the  
10 art.

Preferred methods of obtaining double-stranded cDNA from isolated mRNA include synthesizing a single-stranded cDNA on the mRNA template using a reverse transcriptase, degrading the RNA hybridized to the cDNA strand using a ribonuclease  
15 (RNase), and synthesizing a complementary DNA strand by using a DNA polymerase to give a double-stranded cDNA. Especially preferred methods of preparing cDNA include methods known to those skilled in the art, including, but not limited to, methods wherein total RNA is isolated from vertebrate adipose  
20 or skeletal muscle tissue is converted into single-stranded cDNA using Murine Leukemia Virus Reverse Transcriptase and RNase inhibitor, followed by a PCR procedure to amplify the target cDNA, yielding double-stranded cDNA.

cDNA encoding a protein of the present invention, along  
25 with the other cDNA if a library is constructed as above, are then ligated into cloning vectors. Cloning vectors include a DNA sequence which accommodates the cDNA. The vectors containing the amplified cDNA or cDNA library are introduced into host cells that can exist in a stable manner and provide  
30 an environment in which the cloning vector is replicated. Suitable cloning vectors include plasmids, bacteriophages,

viruses and cosmids. Preferred cloning vectors include plasmids. Cloning vectors which are especially preferred in the isolation methods described herein for the preparation of RT-PCR products from total adipose tissue RNA include the  
5 plasmid pAMP 1.

The construction of suitable cloning vectors containing cDNA and control sequences employs standard ligation and restriction techniques which are well known in the art. Isolated plasmids, DNA sequences or synthesized  
10 oligonucleotides are cleaved, tailored and relegated in the form desired. With respect to restriction techniques, site-specific cleavage of cDNA is performed by treating with suitable restriction enzyme under conditions which are generally understood in the art, and particulars of which are  
15 specified by the manufacturers of these commercially available restriction enzymes. See, e.g., the product catalogs of New England Biolabs, Promega, and Stratagene Cloning Systems.

Cloning vectors containing the desired cDNA are  
20 introduced into host cells and cultured. Cloning vectors containing a cDNA library prepared as disclosed are introduced into host cells, the host cells are cultured, plated, and then probed with a hybridization probe to identify clones which contain the recombinant cDNA encoding a  
25 protein of the present invention. Preferred host cells include bacteria when plasmid cloning vectors are used. Especially preferred host cells include *E. coli* strains such as *E. coli* DH5 $\alpha$ MCR competent cells.

Hybridization probes and primers are oligonucleotide  
30 sequences which are complementary to all or part of the cDNA molecule that is desired. They may be prepared using any

suitable method, for example, the phosphotriester and phosphodiester methods, described respectively in Narang *et al.*, *Methods in Enzymology*, 68:90 (1979) and Brown *et al.*, *Methods in Enzymology*, 68:109 (1979), or automated  
5 embodiments thereof. In one such embodiment, diethylphosphoramidites are used as starting materials and may be synthesized as described by Beaucage *et al.*, *Tetrahedron Letters*, 22:1859-1862 (1981). One method for synthesizing oligonucleotides on a modified solid support is  
10 described in U.S. Patent No. 4,458,066. Probes differ from primers in that they are labeled with an enzyme, such as horseradish peroxidase, or with a radioactive atom, such as  $^{32}\text{P}$ , to facilitate their detection. A synthesized probe is radio-labeled by nick translation using *E. coli* DNA  
15 polymerase I or by end labeling using alkaline phosphatase and T4 bacteriophage polynucleotide kinase.

Useful hybridization probes and amplification primers include oligonucleotide sequences which are complementary to a stretch of the cDNA encoding a portion of the amino acid  
20 sequence of UCP-3, for example, a portion of the amino acid sequence shown in Figure 5. Especially preferred as hybridization probes are oligonucleotide sequences encoding substantially all of the amino acid sequence of human UCP-3. Other appropriate probes for isolation of vertebrate UCP-3  
25 genes will be apparent to those skilled in the art. Especially preferred as amplification primers are pairs of oligonucleotide sequences that flank substantially all of the DNA sequence encoding vertebrate UCP-3, for example, those encoding rat, mouse, or human UCP-3. A preferred cDNA  
30 molecule encoding a vertebrate protein of the present invention can be identified by screening or amplification

methods through its ability to hybridize to these probes or primers.

Upon identification of the clone containing the desired cDNA, whether by an RT-PCR procedure or through cDNA library screening, for example, amplification may be used to produce large quantities of a gene encoding a protein of the present invention in the form of a recombinant cDNA molecule. Preferred methods of amplification include the use of the polymerase chain reaction (PCR). See, e.g., *PCR Technology*, W.H. Freeman and Company, New York (Edit. Erlich, H.A. 1992). PCR is an *in vitro* amplification method for the synthesis of specific DNA sequences. In PCR, two oligonucleotide primers that hybridize to opposite strands and flank the region of interest in the cDNA of the clone are used. A repetitive series of cycles involving cDNA denaturation into single strands, primer annealing to the single-stranded cDNA, and the extension of the annealed primers by DNA polymerase results in numbers of copies of cDNA, whose termini are defined by the 5' ends of the primers, approximately doubling at every cycle. Through PCR amplification, the coding domain and any additional primer encoded information such as restriction sites or translational signals (signal sequences, start and/or stop codons) of the recombinant cDNA molecule to be isolated is obtained. Preferred conditions for amplification of cDNA are found in manufacturer protocols, and may be accomplished manually or by automated thermocycling devices. An example of a cDNA prepared in this fashion is that having the nucleic acid sequence of Figure 1.

The cDNA molecules of the present invention when isolated as described are used to obtain expression of the UCP-3s described and claimed herein. Generally, a

recombinant cDNA molecule of the present invention is incorporated into an expression vector, this expression vector is introduced into an appropriate host cell, the host cell is cultured, and the expressed protein is isolated.

5        Expression vectors are DNA sequences that are required for the transcription of cloned copies of genes and translation of their mRNAs in an appropriate host. These vectors can express either procaryotic or eucaryotic genes in a variety of cells such as bacteria, yeast, mammalian, plant  
10 and insect cells. Proteins may also be expressed in a number of virus systems.

Suitably constructed expression vectors contain an origin of replication for autonomous replication in host cells, or are capable of integrating into the host cell  
15 chromosomes. Such vectors will also contain selective markers, a limited number of useful restriction enzyme sites, a high copy number, and strong promoters. Promoters are DNA sequences that direct RNA polymerase to bind to DNA and initiate RNA synthesis; strong promoters cause such  
20 initiation at high frequency. The preferred expression vectors of the present invention are operatively linked to a cDNA or recombinant cDNA of the present invention, i.e., the vectors are capable of directing both replication of the attached cDNA or recombinant cDNA molecule and expression of  
25 the protein encoded by the cDNA or recombinant cDNA molecule. Expression vectors may include, but are not limited to cloning vectors, modified cloning vectors and specifically designed plasmids or viruses. With each type of host cell certain expression vectors are preferred.

30        Procaryotes may be used and are presently preferred for expression of UCP-3. Suitable bacteria host cells include

the various strains of *E. coli*, *Bacillus subtilis*, and various species of *Pseudomonas*. In these systems, plasmid vectors which contain replication sites and control sequences derived from species compatible with the host are used.

- 5 Suitable vectors for *E. coli* are derivatives of pBR322, a plasmid derived from an *E. coli* species by Bolivar *et al.*, *Gene*, 2:95 (1977). Common procaryotic control sequences, which are defined herein to include promoters for transcription, initiation, optionally with an operator, along  
10 with ribosome binding site sequences, include the beta-lactamase and lactose promoter (Chang *et al.*, *Nature*, 198:1056 (1977)), the tryptophan promoter system (Goeddel *et al.*, *Nucleic Acids Res.*, 8:4057 (1980)) and the lambda-derived  $P_L$  promoter and N-gene ribosome binding site  
15 (Shimatake *et al.*, *Nature*, 292:128 (1981)). However, any available promoter system compatible with procaryotes can be used. Preferred procaryote expression systems include *E. coli* and their expression vectors, such as *E. coli* strains W3110 and JM105, with suitable vectors. Especially preferred  
20 is the use of *E. coli* strain BL21(DE3), with suitable vectors.

- Eucaryotes may be used for expression of the proteins of the present invention. Eucaryotes are usually represented by the yeast and mammalian cells. Suitable yeast host cells  
25 include *Saccharomyces cerevisiae* and *Pichia pastoris*. Suitable mammalian host cells include COS and CHO (Chinese Hamster Ovary) cells, NIH3T3, HEK293, and 3T3L1 cells. Expression vectors for the eucaryotes are comprised of promoters derived from appropriate eucaryotic genes.  
30 Suitable promoters for yeast cell expression vectors include promoters for synthesis of glycolytic enzymes, including



those for the 3-phosphoglycerate kinase gene in *Saccharomyces cerevisiae* (Hitzman et al., *J. Biol. Chem.*, 255:2073 (1980)) and those for the metabolism of methanol such as the alcohol oxidase gene in *Pichia pastoris* (Stroman et al., U.S. Patent Nos. 4,808,537 and 4,855,231). Other suitable promoters include those from the enolase gene (Holland et al., *J. Biol. Chem.*, 256:1385 (1981)) or the Leu2 gene obtained from YEp13 (Broach et al., *Gene*, 8:121 (1978)).

Suitable promoters for mammalian cell expression vectors include the early and late promoters from SV40 (Fiers et al., *Nature*, 273:113 (1978)) or other viral promoters such as those derived from polyoma, adenovirus II, bovine papilloma virus or avian sarcoma viruses. Suitable viral and mammalian enhancers may also be incorporated into these expression vectors.

Suitable promoters for plant cell expression vectors include the nopaline synthesis promoter described by Depicker et al., *Mol. Appl. Gen.*, 1:561 (1978). Suitable promoters for insect cell expression vectors include modified versions of the system described by Smith et al., U.S. Patent No. 4,475,051. The expression vector comprises a baculovirus polyhedrin promoter under whose control a cDNA molecule encoding a protein can be placed.

Another method of producing UCP-3 comprises the steps of culturing a transformed host cell containing a DNA sequence encoding a vertebrate UCP-3, preferably human UCP-3 and isolating the UCP-3 expressed by the transformed host cell. The host cell may be, for example, a yeast cell or other eukaryotic cell. Yeast cells are particularly preferred where the host cell will be used in an *in vivo* assay system for UCP-3 activity.

Expression of UCP-3 in a mammalian cell line where UCP-3 is not normally expressed, such as CHO, COS, NIH3T3, HEK293, or 3T3L1 cell lines is achieved using standard methods of stable transfection (Sambrook). A vector is constructed containing UCP-3 that allows inducible expression of UCP-3 in response to, for instance, the glucocorticoid analog, Dexamethasone or in response to removal of the antibiotic tetracycline. These inducible promoter systems are available commercially (Pharmacia and Clontech). Expression of UCP-3 in an inducible system allows the cells to grow normally in the absence of the predicted warming effects of ectopic expression of UCP-3 until the cells are at sufficient density to be used for the screening application, at which time UCP-3 expression may be readily induced.

Alternatively, UCP-1 and UCP-2 have successfully been expressed in yeast (Murdza-Inglis, D.L., et al. *JBC*. 260:11871-11875 (1991); Bathgate, B. et al. *Mol. Microbiol.* 6:363-37 (1992); Fleury, C., et al., *Nature Genetics*, 15:269-272 (1997)). Yeast vectors for the expression of UCP-3 in yeast preferably consist of an inducible promoter system such as the galactokinase gene enhancer/promoter, GAL1 (Mumberg, D., et al., *Nucleic Acids Res.* 22:5606-5768 (1994)). In this system, transcription is tightly repressed by addition to the growth medium of glucose but upon addition of galactose expression is induced to high levels. Deletions of this promoter and/or use of different plasmid types that direct replication to high or low copy numbers will allow expression levels of UCP-3 to be varied to achieve those optimal for both yeast survival and UCP-3 detection (Mumberg, D., et al., *Nucleic Acids Res.* 22:5767-5768 (1994)). The UCP-3 cDNA can also be modified so as to be optimal for

expression in yeast cells: work with UCP-1 has shown that removal of the 5' and 3' untranslated regions of UCP-1 cDNA and modification of the UCP-1 sequence surrounding the methionine start codon to more closely resemble that normally  
5 found in yeast genes greatly improves expression levels in yeast (Murdza-Inglis, D.R., et al. JBC. 260:11871-11875 (1991); Bathgate B., et al., Mol. Microbiol. 6:363-370 (1992)). These modifications can be readily achieved using PCR mutagenesis approaches such as are well known to those  
10 skilled in the art. In either case, yeast expression or mammalian expression, the UCP-3 gene can be additionally engineered, or not, by in frame addition, at the carboxy terminus of the UCP-3 cDNA, of an oligonucleotide sequence encoding a short peptide that is a characterized epitope,  
15 such as the commercially available FLAG system (Eastman Kodak Comp., New Haven, CT), or poly-histidine. This allows UCP-3 expression level and mitochondrial targeting to be monitored by the use of commercially available antibodies directed against the peptide epitope. The qualitative properties of  
20 yeast lines containing epitope tagged or wildtype UCP-3 will be compared to confirm that the peptide tag does not interfere with normal function. The use of such short sequence tags as markers for the detection of an expressed protein, as well as for purification of the expressed protein  
25 by affinity chromatography is known to those skilled in the art, and described in, for example, P.C.T. Application, US96/04909, published as WO-96-31526, October 10, 1996, hereby incorporated by reference in its entirety.

The recombinant UCP-3 containing yeast cells or  
30 mammalian cell lines are expanded under non-inducing conditions and prior to screening are subjected to induction

to allow UCP-3 production and insertion into mitochondrial membranes. Compounds (UCP-3 activators) may be identified by comparing their ability to stimulate respiration or metabolic activity of UCP-3-expressing cells, compared to control  
5 cells, which may be untransfected cells of the same genetic background. Alternatively, isolated mitochondrial preparations are used to screen for UCP-3 activators, either by measuring stimulation of respiration, or by measuring mitochondrial swelling in a suitable buffer system.

10 Where UCP-3 is to be isolated from the host cell, a prokaryotic cell such as *E. coli* may be used for UCP-3 expression. A number of recombinant production methods are described by contributors to Protein Purification - Micro to Macro, R. Burgess ed., Alan R. Liss, Inc., New York, 1987,  
15 and examples of periplasmic expression of recombinant proteins are given by H. Lee and P. Troota in Purification and Analysis of Recombinant Proteins, R. Seetharam and S. Sharma ed. Marcel Dekker, Inc., New York, 1991, p. 163-181. Provided herein are preferred methods for the periplasmic  
20 expression and purification of UCP-3, which provide increased protein yield and quality. These methods include the use of a T7 promoter vector construct transfected into *E. coli* BL21(DE3) cells which are grown at about 25° to about 30°C in media containing a supplemental carbon source, preferably  
25 glucose, for enhanced expression. Preferred purification methods include the use of an osmotic shock protocol which incorporates one or more specific protease inhibitors, preferably Peflabloc SC, followed by the addition of BisTris-propane, or buffers of a similar nature, and separation using  
30 a cellulose-based anion exchange chromatography resin, preferably DE-52 resin. Further purification may be

undertaken using high pressure liquid chromatography, preferably reversed phase high pressure liquid chromatography. Such methods are described in the below Examples.

5 Intracellular expression can be used to make proteins in *E. coli*, but the production process is complicated by the need to dissolve the inclusion bodies using chaotropic agents and the difficulties inherent in refolding disulfide-bonded proteins, as discussed in Protein Refolding, G. Georgiou and E. Bernardez-Clark eds., (1991), American  
10 Chemical Society, Washington, DC. Also provided herein are preferred methods for the intracellular expression (into inclusion bodies) of recombinant UCP-3, and its subsequent solubilization, refolding and purification, which provide  
15 greatly increased protein yield in *E. coli*. In this method, certain naturally-occurring nucleotides within particular codons in the coding sequences for any of the mammalian UCP-3s, including human, rat and mouse (which are not part of the set of deleterious codons AGG/AGA, CUA, AUA, CGA, or CCC,  
20 described by J. Kane, Curr. Opin. Biotechnol. (1995), 6:494-500), are replaced.

Solubilization, refolding and purification of the recombinant proteins are accomplished by lysing the cells and washing inclusion bodies in an anionic buffer of  
25 approximately neutral pH, preferably 100mM phosphate at a pH of about 6.5, dissolving the inclusion bodies in a buffer containing a chaotropic agent, such as urea in ammonium bicarbonate buffer, transferring the protein by dialysis or dilution into BisTris-propane or a similar buffer, and  
30 purifying the protein using a cellulose-based anion exchange chromatography resin, preferably DE-52 resin. Further

purification may be undertaken using high pressure liquid chromatography, preferably reversed phase high pressure liquid chromatography.

5 The UCP-3s, derivatives, or analogs described herein may also be prepared through peptide purification.

While recombinant DNA methods of production are preferred, chemical synthesis, using a solid phase synthesis approach or a combination of both solid phase peptide synthesis and solution chemistries offers a further method of  
10 preparation of the UCP-3 products of the invention. Examples of solid phase peptide synthesis include that described by Merrifield, *J. Amer. Chem Soc.*, 85: 2149 (1964), or other equivalent methods known in the chemical arts, such as the method described by Houghten, *Proc. Natl. Acad. Sci.*,  
15 82:5132 (1985).

Typically, an  $\alpha$ -N-carbamoyl protected amino acid and an amino acid attached to the growing peptide chain on a resin are coupled at room temperature in an inert solvent such as dimethylformamide, N-methylpyrrolidinone or methylene  
20 chloride in the presence of coupling agents such as dicyclohexylcarbodiimide and 1-hydroxybenzotriazole in the presence of a base such as diisopropylethylamine. The  $\alpha$ -N-carbamoyl protecting group is removed from the resulting peptide-resin using a reagent such as trifluoroacetic acid or  
25 piperidine, and the coupling reaction repeated with the next desired N-protected amino acid to be added to the peptide chain. Suitable N-protecting groups are well known in the art, with t-butyloxycarbonyl (tBoc) and fluorenylmethoxycarbonyl (Fmoc) being preferred herein.

30 The solvents, amino acid derivatives and 4-methylbenzhydryl-amine resin used in the peptide synthesizer

may be purchased from Applied Biosystems Inc. (Foster City, CA), unless otherwise indicated. The side-chain protected amino acids may be purchased from Applied Biosystems, Inc. and include the following: Box-Arg(Mts), Fmoc-Arg(Pmc), Box-Thr(Bzl), Fmoc-Thr(t-Bu), Box-Ser(Bzl), Fmoc-Ser(t-Bu), Box-Tyr(BrZ), Fmoc-Tyr(t-Bu), Box-Lys(Cl-Z), Fmoc-Lys(Box), Box-Glu(Bzl), Fmoc-Glu(t-Bu), Fmoc-His(Trt), Fmoc-Asn(Trt), and Fmoc-Gln(Trt). Box-His(BOM) was purchased from Applied Biosystems, Inc. or Bachem Inc. (Torrance, CA). Anisole, methylsulfide, phenol, ethanedithiol, and thioanisole may be obtained from Aldrich Chemical Company (Milwaukee, WI). Air Products and Chemicals (Allentown, PA) supplied HF. Ethyl ether, acetic acid and methanol may be purchased from Fisher Scientific (Pittsburgh, PA).

Solid phase peptide synthesis is carried out with an automatic peptide synthesizer (Model 430A, Applied Biosystems Inc., Foster City, CA) using the NMP/HOBt (Option 1) system and tBoc or Fmoc chemistry (see, Applied Biosystems User's Manual for the ABI 430A Peptide Synthesizer, Version 1.3B July 1, 1988, section 6, pp. 49-70, Applied Biosystems, Inc., Foster City, CA) with capping. Box-peptide-resins are cleaved with HF (-5EC to 0EC, 1 hour). The peptide is extracted from the resin with alternating water and acetic acid, and the filtrates were lyophilized. The Fmoc-peptide resins are cleaved according to standard methods (Introduction to Cleavage Techniques, Applied Biosystems, Inc., 1990, pp. 6-12). Some peptide is also assembled using an Advanced Chem Tech Synthesizer (Model MPS 350, Louisville, Kentucky). Peptides were purified by RP-HPLC (preparative and analytical) using a Waters Delta Prep 3000 system. A C4, C8 or C18 preparative column (10 F, 2.2 x 25 cm; Vydac,

Hesperia, CA ) is used to isolate peptides, and purity is determined using a C4, C8 or C18 analytical column (5 F, 0.46 x 25 cm; Vydac). Solvents (A=0.1% TFA/water and B=0.1% TFA/CH<sub>3</sub>CN) is delivered to the analytical column at a flowrate of 1.0 ml/min and to the preparative column at 15 ml/min. Amino acid analyses is performed on the Waters Pico Tag system and processed using the Maxima program. The peptides are hydrolyzed by vapor-phase acid hydrolysis (115EC, 20-24 h). Hydrolysates are derivatized and analyzed by standard methods (Cohen, S.A., Meys, M., and Tarrin, T.L. (1989), The Pico Tag Method: A Manual of Advanced Techniques for Amino Acid Analysis, pp. 11-52, Millipore Corporation, Milford, MA). Fast atom bombardment analysis was carried out by M-Scan, Incorporated (West Chester, PA). Mass calibration is performed using cesium iodide or cesium iodide/glycerol. Plasma desorption ionization analysis using time of flight detection is carried out on an Applied Biosystems Bio-Ion 20 mass spectrometer.

Peptide compounds useful in the invention may also be prepared using recombinant DNA techniques, using methods now known in the art. See, e.g., Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2d Ed., Cold Spring Harbor (1989).

UCP-3 analogs or derivatives are included within the methods of the present invention. UCP-3 analogs or derivatives are functional equivalents having similar amino acid sequence and retaining, to some extent, the thermogenic or other UCP-3-associated activity of UCP-3. By a "functional equivalent" is meant the derivative has an activity that can be substituted for one or more activities of UCP-3. Preferred functional equivalents retain all of the activities



of UCP-3, however, the functional equivalent may have an activity that, when measured quantitatively, is stronger or weaker, as measured in UCP-3 functional assays. Preferred functional equivalents have activities that are within about 5 1% to about 10,000% of the activity of UCP-3, more preferably between about 10% to about 1000%, and more preferably within about 50% to about 500%. Derivatives have at least about 50% sequence similarity, preferably about 70%, more preferably about 90%, and even more preferably about 95% sequence 10 similarity to UCP-3. "Sequence similarity" refers to "homology" observed between amino acid sequences in two different polypeptides, irrespective of polypeptide origin.

The ability of the derivative to retain some activity can be measured using techniques described herein. 15 Derivatives include modifications occurring during or after translation, for example, by phosphorylation, glycosylation, crosslinking, acylation, proteolytic cleavage, linkage to an antibody molecule, membrane molecule or other ligand (see Ferguson et al., *Annu. Rev. Biochem.* 57:285-320, 1988).

20 Specific types of derivatives also include amino acid alterations such as deletions, substitutions, additions, and amino acid modifications. A "deletion" refers to the absence of one or more amino acid residue(s) in the related polypeptide. An "addition" refers to the presence of one or 25 more amino acid residue(s) in the related polypeptide. Additions and deletions to a polypeptide may be at the amino terminus, the carboxy terminus, and/or internal. Amino acid "modification" refers to the alteration of a naturally occurring amino acid to produce a non-naturally occurring 30 amino acid. A "substitution" refers to the replacement of one or more amino acid residue(s) by another amino acid

residue(s) in the polypeptide. Derivatives can contain different combinations of alterations including more than one alteration and different types of alterations.

While the effect of an amino acid change varies depending upon factors such as phosphorylation, glycosylation, intra-chain linkages, tertiary structure, and the role of the amino acid in the active site or a possible allosteric site, it is generally preferred that the substituted amino acid is from the same group as the amino acid being replaced. To some extent the following groups contain amino acids which are interchangeable: the basic amino acids lysine, arginine, and histidine; the acidic amino acids aspartic and glutamic acids; the neutral polar amino acids serine, threonine, cysteine, glutamine, asparagine and, to a lesser extent, methionine; the nonpolar aliphatic amino acids glycine, alanine, valine, isoleucine, and leucine (however, because of size, glycine and alanine are more closely related and valine, isoleucine and leucine are more closely related); and the aromatic amino acids phenylalanine, tryptophan, and tyrosine. In addition, although classified in different categories, alanine, glycine, and serine seem to be interchangeable to some extent, and cysteine additionally fits into this group, or may be classified with the polar neutral amino acids.

While proline is a nonpolar neutral amino acid, its replacement represents difficulties because of its effects on conformation. Thus, substitutions by or for proline are not preferred, except when the same or similar conformational results can be obtained. The conformation conferring properties of proline residues may be obtained if one or more of these is substituted by hydroxyproline (Hyp).

Examples of modified amino acids include the following:  
altered neutral nonpolar amino acids such as amino acids of  
the formula  $H_2N(CH_2)_nCOOH$  where  $n$  is 2-6, sarcosine (Sar), t-  
butylalanine (t-BuAla), t-butylglycine (t-BuGly), N-methyl  
5 isoleucine (N-MeIle), and norleucine (Nleu); altered neutral  
aromatic amino acids such as phenylglycine; altered polar,  
but neutral amino acids such as citrulline (Cit) and  
methionine sulfoxide (MSO); altered neutral and nonpolar  
amino acids such as cyclohexyl alanine (Cha); altered acidic  
10 amino acids such as cysteic acid (Cya); and altered basic  
amino acids such as ornithine (Orn).

Preferred derivatives have one or more amino acid  
alteration(s) which do not significantly affect thermogenic  
or other UCP-3-associated activity of UCP-3. In regions of  
15 the UCP-3 peptide not necessary for UCP-3 activity, amino  
acids may be deleted, added or substituted with less risk of  
affecting activity. In regions required for UCP-3 activity,  
amino acid alterations are less preferred as there is a  
greater risk of affecting UCP-3 activity. Such alterations  
20 should be conservative alterations. For example, one or more  
amino acid residues within the sequence can be substituted by  
another amino acid of a similar polarity which acts as a  
functional equivalent.

Conserved regions tend to be more important for protein  
25 activity than non-conserved regions. Standard procedures can  
be used to determine the conserved and non-conserved regions  
important of receptor activity using *in vitro* mutagenesis  
techniques or deletion analyses and measuring receptor  
activity as described by the present disclosure.

30 Derivatives can be produced using standard chemical  
techniques and recombinant nucleic acid molecule techniques.

Modifications to a specific polypeptide may be deliberate, as through site-directed mutagenesis and amino acid substitution during solid-phase synthesis, or may be accidental such as through mutations in hosts which produce the polypeptide.

5 Polypeptides including derivatives can be obtained using standard techniques such as those described in Sambrook, et al., Molecular Cloning, Cold Spring Harbor Laboratory Press (1989).

UCP-3 agonists or UCP-3 analogs may also consist of UCP-  
10 3 fragments. Such fragments preferably have deletions of amino acids at either the amino- or carboxy-terminus. Fragments may be prepared by cleavage of the full length UCP-3 or by recombinant DNA-mediated or chemical synthesis of UCP-3 and UCP-3 derivatives.

15 Gene and oligonucleotide therapy methods of the present invention include the use of nucleic acid encoding functioning UCP-3 and the use of inhibitory oligonucleotides. Inhibitory oligonucleotides include antisense nucleic acids and ribozymes. Gene and oligonucleotide therapy can be  
20 performed *ex vivo* on cells which are then transplanted into a patient, or can be performed by direct administration of the nucleic acid or nucleic acid-protein complex into the patient.

Antisense oligonucleotides and ribozymes can be  
25 administered to a patient using different techniques such as by naked nucleic acid, nucleic acid compositions (for example, encapsulated by a liposome) and by retroviral vectors. Miller, Nature 357; 455-460, hereby incorporated by reference herein. Antisense oligonucleotides and ribozymes  
30 can also be introduced into a cell using nucleic acid encoding the antisense nucleic acid or ribozyme.

Gene therapy can be achieved by transferring a gene encoding UCP-3, or a compound that increases the expression of UCP-3, by, for example, inducing the UCP-3 promoter, into a patient in a manner allowing expression of UCP-3.

5 Recombinant nucleic acid molecules encoding UCP-3 can be introduced into a cell *in vivo* or *ex vivo*. *In vivo* transfection techniques include the use of liposomes and retroviral vectors. Miller, *Nature* 357; 455-460, hereby incorporated by reference herein. *Ex vivo* transfection  
10 increases the number of available transfection techniques, but also adds additional complications due to removal and subsequent insertion of cells into a patient.

In preferred embodiments of the current invention, the nucleic acid utilized for gene therapy comprises a nucleic  
15 acid molecule which encodes the amino acid molecule of Figure 5. More preferably the nucleic acid comprises the nucleic acid molecule of Figure 5, or a portion thereof; and/or the oligonucleotides utilized for oligonucleotide therapy are targeted to a nucleic acid coding for UCP-3, more preferably  
20 a nucleic acid coding for the amino acid sequence of Figure 5.

The present invention also contemplates antibodies and immunoassays useful for detecting the presence or amount of UCP-3 or a protein fragment of UCP-3. These antibodies have  
25 various uses such as being used as therapeutic agents to modulate UCP-3 activity; as diagnostic tools for determining the level of UCP-3 expression in a particular tissue and/or the UCP-3 functional integrity to diagnose a UCP-3 or thermogenic-related disease; and as research tools for  
30 studying UCP-3 synthesis, structure, and function. For example, antibodies targeted to UCP-3 are useful to elucidate

The general methodology and steps of antibody assays are described by Greene, U.S. Patent 4,376,110, entitled

One such immunoassay is a sandwich immunoassay, and comprises the steps of (1) reacting an immobilized anti-UCP-3 antibody, preferably a monoclonal antibody, and a labeled anti-UCP-3 antibody, preferably a monoclonal antibody, which recognizes a different site from that recognized by the immobilized antibody, with a sample containing or suspected of containing UCP-3 so as to form a complex of immobilized antibody-UCP-3, and (2) detecting the presence or amount of UCP-3 by determining the presence or amount of label in the complex. In this process the reaction of the immobilized antibody and labeled antibody with the sample may be carried out either simultaneously or separately.

Antibodies that recognize UCP-3 can be prepared from hybridomas by the following method. UCP-3, peptides, or fragments thereof in an amount sufficient to promote formation of antibodies, are emulsified in an adjuvant such as Freund's complete adjuvant. The immunogen may be either crude or partially purified, and is administered to a mammal, such as mice, rats or rabbits, by intravenous, subcutaneous, intradermic, intramuscular, or intraperitoneal injection. In the preparation of polyclonal antibodies, after completion of the immunization protocol, sera are recovered from the immunized animals. In the preparation of monoclonal antibodies, after completion of the immunization protocol, animal spleens are harvested and myeloma cells having a suitable marker such as 8-azaguanine resistance can be used as parent cells which are then fused with the antibody-producing spleen cells to prepare hybridomas. Suitable media for the preparation of hybridomas according to the present invention include media such as Eagle's MEM, Dulbecco's modified medium, and RPMI-1640. Myeloma parent cells and spleen cells can be suitably fused at a ratio of approximately 1:4. Polyethylene glycol (PEG) can be used as a suitable fusing agent, typically at a concentration of about 35% for efficient fusion. Resulting cells may be selected by the HAT method. (Littlefield, J. W., *Science* 145:709 (1964)). Screening of obtained hybridomas can be performed by conventional methods, including an immunoassay using culture supernatant of the hybridomas to identify a clone of hybridoma producing the objective immunoglobulin. The antibody-producing hybridoma obtained can then be cloned using known methods such as the limiting dilution method.

In order to produce, for example, the anti-UCP-3

monoclonal antibodies of the present invention, the hybridoma obtained above may be cultured either in vitro or in vivo. If the hybridoma is cultured in vitro, the hybridoma may be cultured in the above-mentioned media supplemented with fetal calf serum (FCS) for 3-5 days and monoclonal antibodies recovered from the culture supernatant. If the hybridoma is cultured in vivo, the hybridoma may be implanted in the abdominal cavity of a mammal, and after 1-3 weeks the ascites fluid collected to recover monoclonal antibodies therefrom. Much larger quantities of the monoclonal antibodies can efficiently be obtained using in vivo cultures rather than in vitro cultures and, thus, in vivo cultures are preferred. The monoclonal antibody obtained from the supernatant or ascites fluids can be purified by conventional methods such as ammonium sulfate-fractionation, Protein G-Sepharose column chromatography, or their combinations.

Antibodies, or the desired binding portions thereof including F(ab) and Fv fragments, along with antibody-based constructs such as single chain Fv's can also be generated using processes which involve cloning an immunoglobulin gene library in vivo. See, e.g., Huse et al., Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda, (1989) *Science* 246:1275-1281. Using these methods, a vector system is constructed following a PCR amplification of messenger RNA isolated from spleen cells with oligonucleotides that incorporate restriction sites into the ends of the amplified product. Separate heavy chain and light chain libraries are constructed and may be randomly combined to coexpress these molecules together and screened for antigen binding. Single chain antibodies and fragments may also be prepared by this method.



Antibodies according to the present invention can suitably be immobilized on commercially available carriers for the antigen-antibody reaction including beads, balls, tubes, and plates made of glass or synthetic resin. Suitable  
5 synthetic resins include polystyrene and polyvinyl chloride. Anti-UCP-3 monoclonal antibodies are suitably absorbed onto the carrier by allowing them to stand at 2-8°C overnight in 0.05M carbonate buffer, pH 9-10, preferably about pH 9.5. The immobilized anti-UCP-3 monoclonal antibody can be stored  
10 cold in the presence of preservatives such as sodium azide. Both monoclonal and polyclonal antibodies can be immobilized onto carriers using this method.

Labeled UCP-3 antibodies in accordance with the present invention can suitably be prepared by labeling anti-UCP-3  
15 antibodies with any substance commonly used for an immunoassay including radioisotopes, enzymes, and fluorescent substrates. Radioisotopes and enzymes are preferably used. When radioisotopes are used as labels, the antibody is preferably labeled with <sup>125</sup>I using conventional methods such  
20 as the Chloramine T method (Hunter *et al.*, *Nature* (1962) 194:495) and the Bolton-Hunter method. When enzymes are used as labels, the antibody is labeled with an enzyme such as horseradish peroxidase, β-D-galactosidase, or alkaline phosphatase by conventional methods including the maleimide  
25 method and the Hingi method. Ishikawa *et al.*, (1983) *J. Immunoassay* 4:1.

The activity of the label can be detected by conventional methods. If radioisotopes are used as labels, the activity of the label can be detected using an  
30 appropriate instrument such as a scintillation counter. If enzymes are used as labels, the activity of the label can be

detected by measuring absorbance, fluorescence intensity, or luminescence intensity after reacting the enzyme with an appropriate substrate.

The present invention also provides a kit for assaying  
5 the amount of UCP-3, in either biological samples or samples of UCP-3. One example of such a kit comprises an immobilized anti-UCP-3 monoclonal antibody and a labeled anti-UCP-3 monoclonal antibody. When UCP-3s are assayed using this kit, UCP-3 becomes sandwiched between the immobilized monoclonal  
10 antibody and the labeled monoclonal antibody.

The different molecules of the present invention can be used to facilitate diagnosis of UCP-3-related diseases. Diagnosis can be carried out *in vitro* or *in vivo*. For example, the molecules of the present invention can be used  
15 to assay for defects in UCP-3 expression, structure, or activation.

Nucleic acid probes can be used to identify defects in UCP-3 occurring at the genetic level. For example, hybridization probes complementary to nucleic acid encoding  
20 UCP-3 can be used to clone UCP-3. The cloned UCP-3 can be inserted into a cell, such as an oocyte, and its responsiveness to a particular UCP-3-regulating compound determined. Another example of using hybridization assay  
probes to detect defects involves using the probes to detect  
25 mRNA levels or the presence of nucleic acid sequences associated with a particular disease. A decreased mRNA level would be consistent with a decreased amount of expressed UCP-3. Alternatively, defects in UCP-3 occurring at the genetic level may be determined by methods known to those skilled in  
30 the art, such as nucleic acid sequencing or PCR, which may reveal deletions or mutations in the UCP-3 nucleic acid

molecule sequence.

The compounds useful in the present invention that regulate the activity of UCP-3 form salts with various inorganic and organic acids and bases. Such salts include salts prepared with organic and inorganic acids, for example, HCl, HBr,  $H_2SO_4$ ,  $H_3PO_4$ , trifluoroacetic acid, acetic acid, formic acid, methanesulfonic acid, toluenesulfonic acid, maleic acid, fumaric acid and camphorsulfonic acid. Salts prepared with bases include ammonium salts, alkali metal salts, e.g. sodium and potassium salts, and alkali earth salts, e.g. calcium and magnesium salts. Acetate, hydrochloride, and trifluoroacetate salts are preferred. The salts may be formed by conventional means, as by reacting the free acid or base forms of the product with one or more equivalents of the appropriate base or acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water which is then removed in vacuo or by freeze-drying or by exchanging the ions of an existing salt for another ion on a suitable ion exchange resin.

20           The compounds of the present invention are useful in  
view of their pharmacological properties. In particular, the  
compounds of the invention possess activity as agents to  
treat or prevent conditions or disorders related to  
thermogenesis such as, for example, obesity, malignant  
25   hyperthermia, and fever.

Compositions useful in the invention may conveniently be provided in the form of formulations suitable for parenteral (including intravenous, intramuscular and subcutaneous) or nasal or oral administration. In some cases, where the composition is administered to prevent or to treat obesity, it will be convenient to provide such compositions along with

a food-intake-reducing, plasma glucose-lowering or plasma lipid-lowering agent, such as amylin, an amylin agonist, a leptin, an exendin, or an ob protein, in a single composition or solution for administration together. In other cases, it  
5 may be more advantageous to administer the additional agent separately from said compound. A suitable administration format may best be determined by a medical practitioner for each patient individually. Suitable pharmaceutically acceptable carriers and their formulation are described in  
10 standard formulation treatises, e.g., Remington's Pharmaceutical Sciences by E.W. Martin. See also Wang, Y.J. and Hanson, M.A. "Parenteral Formulations of Proteins and Peptides: Stability and Stabilizers," Journal of Parenteral Science and Technology, Technical Report No. 10, Supp. 42:2S  
15 (1988).

Compounds useful in the invention can be provided as parenteral compositions for injection or infusion. They can, for example, be suspended in an inert oil, suitably a vegetable oil such as sesame, peanut, olive oil, or other  
20 acceptable carrier. Preferably, they are suspended in an aqueous carrier, for example, in an isotonic buffer solution at a pH of about 5.6 to 7.4. These compositions may be sterilized by conventional sterilization techniques, or may be sterile filtered. The compositions may contain  
25 pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH buffering agents. Useful buffers include for example, sodium acetate/acetic acid buffers. A form of repository or "depot" slow release preparation may be used so that therapeutically  
30 effective amounts of the preparation are delivered into the bloodstream over many hours or days following transdermal

injection or delivery.

The desired isotonicity may be accomplished using sodium chloride or other pharmaceutically acceptable agents such as dextrose, boric acid, sodium tartrate, propylene glycol, polyols (such as mannitol and sorbitol), or other inorganic or organic solutes. Sodium chloride is preferred particularly for buffers containing sodium ions.

The claimed compositions can also be formulated as pharmaceutically acceptable salts (e.g., acid addition salts) and/or complexes thereof. Pharmaceutically acceptable salts are non-toxic salts at the concentration at which they are administered. The preparation of such salts can facilitate the pharmacological use by altering the physical-chemical characteristics of the composition without preventing the composition from exerting its physiological effect. Examples of useful alterations in physical properties include lowering the melting point to facilitate transmucosal administration and increasing the solubility to facilitate the administration of higher concentrations of the drug.

Pharmaceutically acceptable salts include acid addition salts such as those containing sulfate, hydrochloride, phosphate, sulfamate, acetate, citrate, lactate, tartrate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, cyclohexylsulfamate and quinate.

Pharmaceutically acceptable salts can be obtained from acids such as hydrochloric acid, sulfuric acid, phosphoric acid, sulfamic acid, acetic acid, citric acid, lactic acid, tartaric acid, malonic acid, methanesulfonic acid, ethane sulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclohexylsulfamic acid, and quinic acid. Such salts may be prepared by, for example, reacting the free acid or base

forms of the product with one or more equivalents of the appropriate base or acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water which is then removed in vacuo or by freeze-drying or by exchanging  
5 the ions of an existing salt for another ion on a suitable ion exchange resin.

Carriers or excipients can also be used to facilitate administration of the compound. Examples of carriers and excipients include calcium carbonate, calcium phosphate,  
10 various sugars such as lactose, glucose, or sucrose, or types of starch, cellulose derivatives, gelatin, vegetable oils, polyethylene glycols and physiologically compatible solvents. The compositions or pharmaceutical composition can be administered by different routes including intravenously,  
15 intraperitoneal, subcutaneous, and intramuscular, orally, topically, or transmucosally.

If desired, solutions of the above compositions may be thickened with a thickening agent such as methyl cellulose. They may be prepared in emulsified form, either water in oil  
20 or oil in water. Any of a wide variety of pharmaceutically acceptable emulsifying agents may be employed including, for example, acacia powder, a non-ionic surfactant (such as a Tween), or an ionic surfactant (such as alkali polyether alcohol sulfates or sulfonates, e.g., a Triton).

25 Compositions useful in the invention are prepared by mixing the ingredients following generally accepted procedures. For example, the selected components may be simply mixed in a blender or other standard device to produce a concentrated mixture which may then be adjusted to the  
30 final concentration and viscosity by the addition of water or thickening agent and possibly a buffer to control pH or an

additional solute to control tonicity.

For use by the physician, the compositions will be provided in dosage unit form containing an amount of such UCP-3 activity-affecting composition. Those of skill in the art will recognize that the dosage will depend upon the purpose of administering said composition, and the severity of the disease or condition. For the treatment or prevention of obesity, for example, said composition may also comprise a food intake-reducing, plasma glucose-lowering or plasma lipid-lowering agent. In general, therapeutically effective amounts of such compositions are those that achieve the desired thermogenic, or obesity-decreasing effect, such as, for example, those that produce a significant reduction in weight when compared to a placebo-treated population. As will be recognized by those in the field, an effective amount of therapeutic agent will vary with many factors including the age and weight of the patient, the patient's physical condition, the blood sugar level and other factors.

The effective daily dose of such compounds will depend upon the purpose for which the compounds are administered. For example, the daily dose of such compositions for the treatment of obesity will typically be in the range of 0.01 or 0.03 to about 10 mg/day, preferably about 5 to 50mg/day and more preferably about 10 to 250mg/day, for a 70 kg patient, administered in a single or divided doses. The exact dose to be administered is determined by the attending clinician and is dependent upon where the particular compound lies within the above quoted range, as well as upon the age, weight and condition of the individual. Administration should begin at the first sign of symptoms or shortly after diagnosis of obesity. Administration may be by injection,

preferably subcutaneous or intramuscular. Orally active compounds may be taken orally, however dosages should be increased 5-10 fold.

The optimal formulation and mode of administration of compounds of the present application to a patient depend on factors known in the art such as the particular disease or condition, the desired effect, and the type of patient. While the compounds will typically be used to treat human subjects they may also be used to treat similar or identical diseases in other vertebrates such as other primates, farm animals such as swine, cattle and poultry, and sports animals and pets such as horses, dogs and cats.

To assist in understanding the present invention, the following Examples are included. The experiments relating to this invention should not, of course, be construed as specifically limiting the invention and such variations of the invention, now known or later developed, which would be within the purview of one skilled in the art are considered to fall within the scope of the invention as described herein and hereinafter claimed.

#### Example 1: Characterization and Cloning of UCP-3

A database of expressed sequence tags (dbEST) was searched for sequences related to UCP-2. We searched dbEST using one of the family of "BLAST" sequence similarity algorithms (Altschul, S.F., et al., *J. Mol. Biol.* 215:403-410 (1990)) to compare the amino acid sequence of hUCP-2 and to the cDNA database sequences dynamically translated in all 6 reading frames. A single cDNA clone with significant similarity to hUCP-2 was identified. The clone (I.D. 628529) was characterized and its complete nucleotide sequence and



deduced amino acid sequence is presented in Figure 1 (SEQ ID NO. 1).

Clone 628529 encodes an open reading frame (ORF) of 114 amino acids that has significant homology with the carboxy one third of human UCP-1 (see Figure 2 [alignment]). Since there is no in-frame stop or methionine in a suitable start consensus at the 5' end of clone 628529 we conclude that this constitutes a fragment of a longer cDNA encoding a third member of the UCP family that we propose naming UCP-3.

Comparison of the amino acid sequence of clone 628529 to the carboxy one third (approx) of human UCP-1 is shown in Figure 2.

Clone ID 628529 (GenBank Accession No. AA192136), available through the I.M.A.G.E. Consortium (Lennon, G.G., et al., *Genomics* 33:151-152 (1996)), was isolated from a Stratagene library generated from the skeletal muscle of an adult human patient with malignant hyperthermia. This clone (ID 628529) contains an approximately 1.5 kbp insert encoding the 3' one third of the coding region and a stretch of 3' untranslated sequence subcloned into the *EcoRI* and *XhoI* sites of the vector Bluescript SK(-) (Stratagene).

We used the sequence of clone 628529 to derive oligonucleotide primers for a modified 5' RACE (rapid amplification of cDNA ends) protocol to isolate the remaining 5' sequence of the UCP-3 cDNA. The Advantage cDNA PCR kit and KlenTaq polymerase mix and the Marathon human skeletal muscle "Long Runner" cDNA library (both from Clontech) were used. Basically, UCP-3 5' sequence was amplified from the cDNA library using 3' gene-specific primers from two areas of the UCP-3 628529 fragment and 5' primers from the library adapter ends. The UCP-3 antisense primers were from derived

from the region around the predicted stop codon (A850 that spans nucleotides 405 to 381; Table 1), or the 3' end of the fragment (A852 that spans nucleotides 137 to 116; Table 1). The 5' primer was complementary to adapter sequences ligated to all cDNAs in the library and was supplied by the manufacturer (Clontech). Amplification was performed as suggested by the manufacturer and the resultant products were cloned into the pCRII vector (Invitrogen) using the T/A cloning kit (Invitrogen) following the manufacturers instructions.

Table 1. Sequence of UCP-3 primers

Name	Primer Position (Clone 628529 nucleotides)	Primer sequence (5' to 3')
A844	1-22	GGIGACCTACGACACCTCAAG
A845	348-338	CAAAACGGTGATTCCCGTAAC
A850	405-381	CTTCCATTCTTAACTGGTTTCGGAC
A852	137-116	TCTTCACCACGTCCACCGGGGA

The inserts were sequenced on both strands by the dideoxy chain termination method (Sanger, F., *Proc. Natl. Acad. Sci. USA* 74:5463-5467 (1977)) utilizing the Thermo Sequenase™ radiolabeled terminator cycle sequencing protocols (Amersham, Arlington Heights, IL) and [<sup>32</sup>P]dideoxy NTPs. A combination of nested deletion subclones and internal, gene-specific synthetic oligonucleotide primers are used as necessary to obtain the entire sequence.

Oligonucleotides were synthesized (Life Technologies, Inc., Grand Island, NY and Genosys, The Woodlands, TX) for use as primers in polymerase chain reaction (PCR) amplifications. Names, sequences of primers and the positions in clone 6628529 to which they correspond are listed in Table 1.

The complete nucleotide sequence and the deduced amino acid sequence of UCP-3 are shown in Figure 5.

A comparison of the amino acid sequence of UCP-3 with human UCP-1 and UCP-2 is shown in Figure 6.

5        This alignment demonstrates the 56% similarity between UCP-3 and UCP-1, and the 70% similarity between UCP-3 and UCP-2. In UCP-1, the first 9 residues of the sixth transmembrane domain (UCP-1 positions 262-270; Figure 6) correspond to the putative nucleotide recognition element.  
10    Indeed, deletion of Phe<sub>268</sub>-Lys<sub>269</sub>-Gly<sub>270</sub> from UCP-1 resulted in an unregulated uncoupler and demonstrated that those residues are essential for the nucleotide inhibition of UCP-1 proton transport (Bouillaud, F., et al., *EMBO J.* 13:1990-1997 (1994)). The same study also suggests that substituting  
15    Tyr (as found in UCP-3) for Phe<sub>268</sub> increases UCP-1 uncoupling activity.

         Similarly, Arg<sub>277</sub>, conserved in all three members of the family, is directly involved in purine nucleotide regulation of UCP-1 transport function. Mutation of this residue  
20    results in the total abolition of GDP inhibition of UCP-1 proton transport (Murdza-Inglis, D.L., et al., *J. Biol. Chem.* 269:7435-7438 (1994)), although it is not known if Arg<sub>277</sub> is directly involved in the GDP binding.

#### Example 2: Tissue-specific Expression of UCP-3

25        Probe preparation: The UCP-3 probe was prepared as follows: UCP-3 template was prepared from clone 628529. The UCP-3 sequence was excised from the bacterial plasmid Bluescript SK(-) (Stratagene) using restriction digestion with EcoRI and XhoI and resolved by agarose gel  
30    electrophoresis. The hUCP-3 containing band was excised from

the gel and purified using columns following the manufacturer's instructions. The concentration of the purified template DNA was estimated by comparison to DNA standards (Life Technologies) following agarose gel electrophoresis of standards and sample.

This gel purified UCP-3 fragment was PCR amplified to generate a 347bp PCR probe radiolabelled to a specific activity of  $5 \times 10^9$  cpm/ $\mu$ g essentially as described (Schowalter, D.B and Sommer, S.S, *Anal. Biochem.* 177:90-94 (1989)). Approximately 4ng of the gel purified UCP-3 fragment (generated as described above) was amplified in a 20 $\mu$ l reaction containing 10mM Tris-HCl (pH 8.3), 50mM KCl, 1.5mM MgCl<sub>2</sub>, 0.5 $\mu$ M of each of primer A844 and primer A845 (Table 1), 0.2mM dATP, 0.2mM dGTP, 0.2mM dTTP, 2.5mM [ $\alpha$ -<sup>32</sup>P]dCTP (3000Ci/mmol; 150uCi; Amersham). The reaction was heated for 3 minutes at 94°C at which time 1.25U AmpliTaq<sup>®</sup> DNA polymerase (Perkin-Elmer) was added and followed by 30 cycles of denaturation for 30 seconds at 94°C, annealing for 30 seconds at 55°C and extension for 30 seconds at 72°C. A final 10 minute extension was performed at 72°C prior to the removal of unincorporated nucleotides by spin filtration (Ultrafree-MC, Millipore, Bedford, MA) per the manufacturer's protocol.

We examined the distribution of UCP-3 in human tissues using the 347 bp UCP-3 probe (generated as described above) in a Northern analysis of a panel of human and rat tissues. Under high stringency hybridization and wash conditions, an approximately 2.5 kb transcript was observed in human skeletal muscle, but not in human lung, heart, placenta, kidney, pancreas, brain or liver (Figure 3A). Similarly a transcript was observed in rat skeletal muscle but not in rat heart, lung, liver, spleen, kidney, brain or testes (Figure

3B).

Total RNA Northern blots prepared from rat treatment groups or human and rat multiple tissue Northern blots (Clontech; containing 2 $\mu$ g of poly (A)<sup>+</sup> RNA per lane from 8  
5 different human tissues: heart; brain; placenta; lung; liver; skeletal muscle; kidney; pancreas, and eight rat tissues: heart; brain; spleen; lung; liver; skeletal muscle; kidney; testes) were prehybridized for 1 hour at 68°C in ExpressHyb hybridization solution (Clontech) prior to the addition of  
10 the heat denatured <sup>32</sup>P-labeled DNA probe described above. Following hybridization with the probe for 1 hour at 68°C, the blot was washed at low stringency: in 2 X SSC (1 X SSC = 0.15 M NaCl and 0.015 M sodium citrate, pH 7.0) - 0.05% SDS at 60°C and exposed to Kodak XAR film (Eastman Kodak, Rochester,  
15 NY) with an intensifying screen at -80°C. The same blot was then rewashed at high stringency: 0.1 X SSC - 0.1% sodium dodecyl sulfate at 60°C and once again exposed to film.

The tissue-specific expression are determined by utilizing a human RNA dot blot normalized to the poly(A)<sup>+</sup> RNA  
20 expression levels of eight different housekeeping genes (phospholipase, ribosomal protein S9, tubulin, highly basic 23-kDa protein, glyceraldehyde-3-phosphate dehydrogenase, hypoxanthine guanine phosphoribosyl transferase,  $\beta$ -actin, and ubiquitin). The normalization process compensates for  
25 differences in the overall level of transcriptional activity between tissues, as well as tissue-specific variations in the expression of any single housekeeping gene transcript (Spanakis, E. *Nucleic Acids Res.* 21:3809-3819 (1993); Spanakis, E. and Brouty-Boyé, D. *Nucleic Acids Res.* 22:799-  
30 806 (1994)).

A human RNA Master blot (Clontech) containing poly A<sup>+</sup>

RNA from 50 different human tissues and six different control RNAs and DNAs is prehybridized overnight at 65°C in ExpressHyb hybridization solution (Clontech) containing 100µg/ml heat-denatured, sheared salmon sperm DNA. The <sup>32</sup>P-labeled human UCP-3 DNA probe (described above) is mixed with 30µg of human C<sub>0</sub>t-1 DNA (Life Technologies) and 150µg sheared salmon sperm DNA in 5X SSC, heat denatured for 5 min at 99°C, annealed for 30 min at 68°C, and added to 5ml fresh ExpressHyb solution. Following hybridization at 65°C overnight, the blot is washed in 0.1X SSC/0.1% SDS at 68°C and subsequently exposed to Kodak XAR film (Eastman Kodak) with an intensifying screen at -80°C. Image quantification is accomplished with a model GS-250 Molecular Imager and an Imaging Screen-BI using Phosphor Analyst/PC image analysis software (Bio-Rad, Hercules, CA).

15 Example 3: Regulation of UCP-3 expression

UCP-1 expression is known to be upregulated by cold acclimatization (via adrenergic stimulation of the brown fat depots) and by thyroid hormone (T<sub>3</sub>) treatment (Rehmark, S., et al., *J. Biol. Chem.* 265:16464-71 (1990); Ricquier, D., et al., *J. Biol. Chem.* 261:13905-10 (1986); Bianco, A.C., et al., *J. Biol. Chem.* 263:18168-75 (1988)). Therefore we tested whether UCP-3 expression would similarly be regulated, in vivo, by these treatments. UCP-3 transcripts are markedly upregulated by a one week exposure to cold and by treatment of animals with T<sub>3</sub> (Figure 4). The conservation of regulatory mechanisms between UCP-1 and UCP-3 may indicate that these proteins perform similar functions in the body in body temperature regulation and fuel efficiency modulation.

180-200g male HSD rats were fed normal chow and kept in a 12 h light/dark cycle during the seven day treatment

period, with 3-4 animals per group. A "control" group were maintained at 22°C (room temperature). A second group, "T3", were kept at 22°C but with 3.3µg/ml triiodothyronine in their drinking water (animals were drinking approx 30ml/day = 100µg/rat = 500µg/kg) and a third group were maintained at 4°C ("cold acclimatized"). Following the treatment period animals were sacrificed by decapitation and tissues were harvested and immediately snap frozen in liquid N<sub>2</sub>. Total RNA was isolated from skeletal muscle, heart, white and brown fat depots using the "Tri Reagent" following the manufacturer's instructions (Molecular Research Center, Cincinnati, OH). 20µg of RNA was loaded per lane onto 1% denaturing agarose gels and blotted to nitrocellulose membranes following standard protocols (See, e.g., Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2d Ed., Cold Spring Harbor (1989)).

#### Example 4: Screening for Compounds that Regulate UCP-3 Activity

The assays presented herein use brown adipose tissue as a source of UCP-3 activity. Those skilled in the art will recognize that other tissues, such as skeletal muscle tissue, may be used in these assays with modifications appropriate for each tissue, such as those known in the art. These modifications include, for example, changes in the preparation of the tissue. Skeletal muscle tissue mitochondria may be prepared from, for example, soleus muscle or hind limb muscles. To assay UCP-3 in the absence of any other UCP activity, yeast cells transformed with UCP-3 are preferred. Those skilled in the art will recognize that appropriate modifications to the assays may be easily made

for the assay of UCP-3 activity in yeast cells, or in UCP-3 prepared from yeast cells. In addition, UCP-3-transformed cells, or cell-lines that express UCP-3, may be compared to non-UCP-3 transfected cells for activity in the presence or  
5 absence of test compounds in UCP-3-activity assays, for example, such as the assays described in these Examples.

#### Preparation of Brown Adipose Tissue Mitochondria

The intrascapular fat pads are removed from decapitated rats (180 g to 220 g male Lewis rats) into ice cold isolation  
10 medium containing 20 mM HEPES, 250 mM sucrose, 2mM EDTA, 1% fatty acid-free BSA, pH=7.4, at 4°C. Brown adipose tissue (BAT) is isolated from adjacent muscle, connective tissue, and white fat, is homogenized for 15 seconds (setting 3 on Polytron homogenizer; 1 g BAT/35 ml medium). Homogenate is  
15 centrifuged for 10 minutes x 700 g at 4°C. The suspension is transferred to a second tube and centrifuged for 10 minutes x 8250 g at 4°C. The pellet is resuspended in isolation medium (1 g BAT/35 ml isolation medium). The suspension is  
20 centrifuged for 10 minutes x 8250 g at 4°C. For immediate use in the respiration assay, the pellet is resuspended in 0.35 ml BSA-free isolation medium and held on ice until used. For use in the purine nucleotide binding assay, the pellet is  
resuspended in 3.0 ml BSA-free isolation medium, flash frozen on dry ice in 1.0 ml aliquots, and stored at -70°C until  
25 used.

#### Mitochondrial Membrane Purine Nucleotide Binding Assay

Fifty  $\mu$ l of sample containing the test compound, or assay buffer (containing 250 mM sucrose, 20 mM HEPES, 2 mM EDTA, and 3 $\mu$ M rotenone at pH 7.0) and 50 $\mu$ l of 180 nM  $^3$ H-GDP



are combined in the wells of a 96-well microtiter plate. Incubations are begun by the addition of 50  $\mu$ l BAT mitochondrial suspension containing 1.7 mg original wet weight (Example 1). Nonspecific 3H-GDP binding is determined in the presence of 1 mM unlabeled GDP. After 60 minutes at room temperature, the incubation is stopped by filtration onto a Packard Unifilter using a Packard plate harvester. Filters are washed immediately before filtration with 4 ml phosphate buffered saline (PBS) and immediately after filtration with 12 ml PBS. Filters were dried overnight at room temperature, then counted on a Packard TopCount scintillation counter.

Isolated Brown Adipose Tissue  
Mitochondria Respiration Assay

The oxygen sensor (YSI 5300) is calibrated, maintained, and operated as per manufacturer's instructions. In a 3 ml respiration chamber, 100  $\mu$ M laurate, 50  $\mu$ M guanine nucleotide diphosphate (GDP), appropriate concentrations of test sample or buffer, and 250  $\mu$ g BAT mitochondria are combined in 1 ml respiration medium containing 100 mM KCl and 10 mM TES (pH=7.0) at 25°C. After a 10 minute equilibration period, 10 mM succinate is added to stimulate increased mitochondrial respiration. Oxygen levels in each vessel were continuously recorded during the subsequent 10 to 12 minute period. The rate of oxygen consumption is determined for each sample as % decrease in nmoles  $O_2$  per minute per mg protein, assuming 237 nmoles  $O_2$ /ml respiration medium.

Isolated Brown Adipose Tissue  
Mitochondrial Swelling Assay

Brown adipose tissue mitochondria are isolated as described in section 1, and reconstituted at 4°C in buffer containing 250 mM sucrose and 5mM TES at pH 7.2, at a concentration of approximately 5 mg protein/ml. To initiate swelling, mitochondrial are diluted at least 10 fold (normally 30-40 fold into a buffer containing 100 mM KCl, 5mM TES and 4µM rotenone (to inhibit respiration) at pH 7.2. Mitochondrial are incubated for 2 min at 23°C. Swelling of mitochondrial is recorded by measuring the rate of change of optical density at 560nm in a spectrophotometer (Molecular Devices SPECTRAMax 250). Addition of 0.5 µM valinomycin (a potassium ionophore) to the mitochondrial initiates rapid swelling and addition of GDP (50µM-1mM) markedly inhibits valinomycin-induced swelling.

Whole Cell Respiration Assay

Intrascapular brown fat pads are removed from decapitated rats (100-150g, HSD or Lewis), trimmed of extraneous tissue (white fat and muscle) and rinsed in saline. Tissue is chopped into 250 µM sections using a tissue chopper, and the mince is digested in 2ml of Krebs-Ringer phosphate buffer containing 1mg/ml glucose, 50 mg/ml BSA and 4 mg collagenase (Type II) for 50 min at 37°C in a polyethylene vial in an atmosphere of 95% O<sub>2</sub>/5%CO<sub>2</sub>) with shaking (150 cycles/min). At the end of the digestion period, isolated cells were separated from non-digested tissue by centrifugation (BAT cells float, other cells and undigested tissue pieces sink), and washed several times in collagenase-free buffer. Cells are resuspended in 2ml of

Hanks Balanced Salt Solution (Hanks BSS) containing 10 mM Hepes, 2.7 mM glucose and 10 mg/ml BSA. Cells were counted and diluted to approximately  $7.5 \times 10^4$  cells/ml to be used for oxygen consumption assays. Cells were maintained in an atmosphere of 95%  $O_2$ /5% $CO_2$  and gassed every 30 min. Oxygen consumption is measured as described in Example III. Cells are diluted 1:10 in BSA-free Hanks BSS and 1 ml of cells added to the chamber ( $7.5 \times 10^4$  in 1 mg/ml BSA). Agents that affect cell respiration are added to the chamber once a stable rate of oxygen consumption is obtained. Oxygen consumption is expressed as nmoles/min/ $10^6$  cells, based on a saturation of 950nmol  $O_2$ /ml.

#### Whole Animal Respiration Assay

Plexi-glass animal holding chambers with an approximate capacity of 1 liter are utilized to house the rats for indirect calorimetry. Each plexi-glass housing unit has an air intake port and an air exhaust port. Room air, at a flow rate of 0.5 l/min, is drawn past the animals using a multi-channel peristaltic pump (Cole-Parmer Instruments, Illinois). The exhaust from each animal chamber is sampled via a 16 channel port multiplexor for 10 seconds, at 1 minute intervals, for several hours to measure the Nitrogen, Oxygen and Carbon dioxide concentrations, using an MGA-3000, mass spectrometer gas analyzer (Airspec, England). During each sampling cycle, calibration gas (75% Nitrogen, 15% Oxygen, 5% Carbon dioxide, 5% Argon) is sampled to assure that the mass spectrometer is calibrated. These values are used to correct any drift in the  $O_2$  and  $CO_2$  measurement that may occur. Room air is also sampled during each sampling cycle, so that  $O_2$  consumption and  $CO_2$  production rate could be calculated by determining the difference between room air and the air

flowing out from the animal chambers. The signals from the mass spectrometer are fed in to an IBM computer system to measure O<sub>2</sub> consumption and CO<sub>2</sub> production rates for each 10 second epoch.

5 Harlan Sprague-Dawley rats (250-300 gms) with chronic intravenous catheters are utilized for screening of compounds. After attaching a syringe, filled with test substance or vehicle, via a polyethylene tubing to the IV cannula, the rats are placed in the indirect calorimetry  
10 animal holding chamber and allowed to habituate for at least 45 minutes. Once the animals are calm, the experiment starts by collecting baseline measurements of O<sub>2</sub> consumption and CO<sub>2</sub> production. After 40 minutes of stable baseline, each animal is injected, via the IV cannula, with either vehicle or test  
15 compound, and the O<sub>2</sub> and CO<sub>2</sub> values monitored for 80 more minutes.

#### Example 5: Cell culture and transfections

HEK-293 cells are transfected with a UCP-3 inducible expression vector. The day before transfection, HEK-293  
20 cells are plated at  $1.2 \times 10^7$  cells per T-162cm<sup>2</sup> flasks (Costar) in maintenance medium: Minimum Essential Medium (Life-Technologies, Inc.) containing 10% fetal bovine serum (Irvine Scientific, Santa Ana, CA) and 2mM L-glutamine (Life-Technologies, Inc.). The following day, the medium is  
25 aspirated and replaced with transfection mixture prepared per the manufacture's recommendations: 10 ml Opti-MEM containing 55μM 2-mercaptoethanol (Life-Technologies, Inc.), 150μg LipofectAMINE (Life-Technologies, Inc.), and 20μg DNA. After 5 hours, the transfection mixture is aspirated and replaced  
30 with HEK-293 maintenance medium containing 50U/ml Penicillin

and 50 $\mu$ g/ml Streptomycin (Life-Technologies, Inc.). For selection stable transfectants, fresh medium containing 250 $\mu$ g/ml Zeocin<sup>TM</sup> (Invitrogen, San Diego, CA) is added 72 hours post-transfection. Cells are maintained at 37°C in 5%  
5 CO<sub>2</sub>-95% humidified air.

Various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the following claims.

WE CLAIM:

1. An isolated nucleic acid molecule which encodes UCP-3.
2. The isolated nucleic acid molecule of claim 1,  
5 wherein said nucleic acid encodes rat UCP-3.
3. The isolated nucleic acid molecule of claim 1,  
wherein said nucleic acid encodes human UCP-3.
4. The isolated nucleic acid molecule of claim 1,  
wherein said nucleic acid encodes an amino acid sequence  
10 comprising the amino acid sequence of Figure 5.
5. The isolated nucleic acid molecule of claim 1,  
comprising the nucleic acid sequence of Figure 5.
6. The isolated nucleic acid molecule of any of claims  
1-5, operably linked to a promoter sequence, wherein said  
15 promoter sequence promotes the transcription of the coding  
region of said nucleic acid.
7. A vector comprising the nucleic acid molecule of  
any of claims 1-5.
8. The vector of claim 7, further comprising a  
20 promoter sequence which is operably linked to said nucleic  
acid molecule.

9. The vector of claim 8, further comprising a 3' polyadenylation sequence which is operably linked to said nucleic acid molecule.

10. A host cell transformed with the vector of claim 7.

5 11. A host cell transformed with the vector of claim 8.

12. A host cell transformed with the vector of claim 9.

13. A UCP-3-expressing host cell transformed with a nucleic acid molecule which encodes UCP-3.

14. Isolated UCP-3.

10 15. The isolated UCP-3 of claim 14, wherein said UCP-3 is isolated from a cell that comprises an endogenous nucleic acid molecule that encodes UCP-3.

15 16. The isolated UCP-3 of claim 14, wherein said UCP-3 is isolated from a cell that is transformed with a nucleic acid molecule that encodes UCP-3.

17. The isolated UCP-3 of claim 14, wherein said UCP-3 is chemically synthesized.

18. An anti-UCP-3 antibody.

20 19. The antibody of claim 18 that binds to an amino acid sequence within the N-terminal region of UCP-3, said N-terminal region comprising amino acids 47-60.

20. The antibody of claim 19 that binds to an amino acid sequence within the N-terminal region of UCP-3, said antibody binding to a region comprising amino acids 303-313.

21. A method of increasing thermogenesis in a subject,  
5 comprising administering to said subject a nucleic acid molecule which encodes UCP-3, wherein said administering of said nucleic acid molecule increases the level of UCP-3 expression in one or more tissues of said subject.

22. A method of treating obesity in a subject,  
10 comprising administering to said subject a nucleic acid molecule which encodes UCP-3, wherein said administering of said nucleic acid molecule increases the level of UCP-3 expression in one or more tissues of said subject.

23. A method of decreasing the amount of fat in a  
15 subject, comprising administering to said subject a nucleic acid molecule which encodes UCP-3, wherein said administering of said nucleic acid molecule increases the level of UCP-3 expression in one or more tissues of said subject.

24. The method of any of claims 21-23, wherein said  
20 tissue is adipose tissue.

25. The method of claim 24, wherein said tissue is white adipose tissue.



5

susceptibility to malignant hyperthermia:

10

or modulates the activity of UCP-3, comprising

compounds into an acceptable medium, and

15

modulate the activity of said UCP-3.

30. The method of claim 29, wherein said monitoring of the binding or modulation of said compound to UCP-3 further comprises

d) monitoring the level of purine nucleotide binding  
5 of UCP-3 in the presence of said compound or compounds; and

e) identifying the compounds that, when in the presence of UCP-3, alter the level of purine nucleotide binding to UCP-3.

31. The method of claim 30, wherein said UCP-3 is  
10 associated with a mitochondrial membrane.

32. The method of claim 30, further comprising the step of monitoring the level of purine nucleotide binding of UCP-3 in the absence of said compound.

33. The method of claim 30, wherein said purine  
15 nucleotide is GDP.

34. The method of claim 29, wherein said monitoring of the binding or modulation of said compound to UCP-3 further comprises

d) monitoring the level of fatty acid binding of UCP-3  
20 in the presence of said compound; and

e) identifying the compounds that, when in the presence of UCP-3, alter the level of fatty acid binding to UCP-3.

35. The method of claim 34, further comprising the step of monitoring the level of fatty acid binding of UCP-3 in the absence of said compound.

36. The method of claim 34, wherein said fatty acid is  
5 laurate.

37. The method of any of claims 29-36, wherein said UCP-3 is rat or mouse UCP-3.

38. The method of any of claims 29-36, wherein said UCP-3 is human UCP-3.

10            39. The method of screening according to any of claims  
29-36, wherein said UCP-3 comprises the amino acid sequence  
of Figure 5.

40. The method of screening according to any of claims  
29-36, wherein said UCP-3 is encoded by a nucleic acid  
15 molecule comprising the nucleic acid sequence of Figure 5.

41. A method of screening for a compound that binds to or modulates the activity of UCP-3, comprising monitoring the effect of said compound on a cell that expresses UCP-3.

42. The method of claim 41, wherein said cell that  
20 expresses UCP-3 is present in skeletal muscle tissue.

43. The method of claim 41, wherein said cell that expresses UCP-3 is present in brown adipose tissue.

44. The method of claim 41, wherein said cell that expresses UCP-3 is transformed with a nucleic acid encoding UCP-3.

5 45. The method of any of claims 41-44, wherein said nucleic acid encodes an amino acid sequence comprising the amino acid sequence of Figure 5.

46. The method of any of claims 41-44, wherein said nucleic acid comprises the nucleic acid sequence of Figure 5.

10 47. The method of any of claims 41-44, further comprising monitoring the effect of said compound on a cell that does not express UCP-3.

48. The method of claim 47, wherein said cell that does not express UCP-3 is otherwise substantially genetically identical to said cell that expresses UCP-3.

15 49. The method of any of claims 41-44, wherein said monitoring of the effect of said compound on said cell comprises monitoring the level of mitochondrial respiration of said cell.

20 50. The method of any of claims 41-44, wherein said monitoring of the effect of said compound on said cell comprises monitoring the level of whole cell or whole animal respiration of said cell.

51. The method of any of claims 41-44, wherein said monitoring of the effect of said compound on said cell comprises monitoring the level of mitochondrial membrane purine nucleotide binding of said cell.

5 52. The method of claim 51, wherein said purine nucleotide is GDP.

53. The method of any of claims 41-44, wherein said monitoring of the effect of said compound on said cell comprises monitoring the level of fatty acid binding of said  
10 cell.

54. The method of claim 53, wherein said fatty acid is laurate.

55. The method according to any of claims 41-44, wherein said UCP-3 is rat or mouse UCP-3.

15 56. The method of screening according to any of claims 41-44, wherein said UCP-3 is human UCP-3.

57. The method of screening according to any of claims 41-44, wherein said UCP-3 comprises the amino acid sequence of Figure 5.

20 58. The method of screening according to any of claim 41-44, wherein said UCP-3 is encoded by a nucleic acid molecule comprising the nucleic acid sequence of Figure 5.

59. The method of any claims 41-44, wherein said cell is selected from the group consisting of yeast cells, COS cells, CHO cells, NIH3T3 cells, HEK-293 cells and 3T3L1 cells.

5 60. The method of claim 59, wherein said cell is a yeast cell.

61. The method of screening according to any of claims 41-44, wherein said compound activates UCP-3 activity.

10 62. The method of screening according to any of claims 41-44, wherein said compound decreases UCP-3 activity.

63. A method of screening for a compound that regulates the expression of UCP-3, comprising monitoring the effect of said compound on the level of expression of UCP-3 RNA in a cell that expresses UCP-3.

15 64. The method of claim 63, wherein said cell that expresses UCP-3 is present in skeletal muscle tissue.

65. The method of claim 63, wherein said cell that expresses UCP-3 is present in brown adipose tissue.

20 66. The method of claim 63, wherein said cell that expresses UCP-3 is transformed with a nucleic acid encoding UCP-3.

67. The method of claim 66, wherein said nucleic acid molecule is operably linked to a UCP-3 native promoter.

68. The method of claim 66, wherein said nucleic acid molecule is operably linked to a heterologous promoter.

69. The method of any of claims 63-66, wherein said nucleic acid encodes an amino acid sequence comprising the  
5 amino acid sequence of Figure 5.

70. The method of any of claims 63-66, wherein said nucleic acid comprises the nucleic acid sequence of Figure 5.

71. The method of claim 66, wherein said cell is selected from the group consisting of yeast cells, COS cells,  
10 CHO cells, NIH3T3 cells, HEK-293 cells, and 3T3L1 cells.

72. The method of claim 71, wherein said cell is a yeast cell.

73. The method of any of claims 63-66, further comprising monitoring the effect of said compound on a cell  
15 that does not express UCP-3.

74. The method of claim 73, wherein said cell that does not express UCP-3 is otherwise substantially genetically identical to said cell that expresses UCP-3.

75. The method of any of claims 63-66, wherein the  
20 level of UCP-3 RNA is determined by probing the messenger RNA expressed said cell with a nucleotide probe that comprises a nucleotide sequence that is homologous to at least 15 consecutive nucleotides of a UCP-3 nucleotide sequence.

76. The method of claim 75, further comprising the step of determining whether the expression of said messenger RNA is increased or decreased compared to the expression of said messenger RNA in a cell that has not been exposed to said  
5 compound.

77. The method of any of claims 63-66, wherein said UCP-3 is human UCP-3.

78. The method of any of claims 63-66, wherein said compound increases the expression of UCP-3.

10 79. The method of any of claims 63-66, wherein said compound decreases the expression of UCP-3.

80. The method of any of claims 63-66, wherein said compound binds to a transcriptional regulatory sequence that increases the expression of UCP-3.

15 81. The method of any of claims 63-66, wherein said compound binds to a transcriptional regulatory sequence that decreases the expression of UCP-3.

82. A method for treating conditions or disorders that can be ameliorated by increasing the level of thermogenesis  
20 in a subject comprising administering to said subject a therapeutically effective amount of a compound that increases the activity of UCP-3.

83. The method of claim 82, wherein said condition or disorder is obesity.



84. A method for treating conditions or disorders that can be ameliorated by decreasing the level of thermogenesis in a subject comprising administering to said subject a therapeutically effective amount of a compound that decreases  
5 the activity of UCP-3.

85. The method of claim 84, wherein said condition or disorder is malignant hyperthermia.

86. The method of claim 84, wherein said condition or disorder is fever.

10 87. The method of claim 84, wherein said administration of said compound decreases UCP-3 activity in the skeletal muscle tissue of said subject.

88. A method of preventing or treating obesity in a subject comprising administering to said subject a  
15 therapeutically effective amount of a compound that increases UCP-3 activity in said subject.

89. The method of claim 88, wherein said UCP-3 activation occurs in the brown adipose tissue or skeletal muscle tissue of said subject.

20 90. The method of claim 88, wherein said increase in UCP-3 activity is associated with an increase in UCP-3 activation.

91. The method of claim 88, wherein said increase in UCP-3 activity is associated with an increase in UCP-3 gene

expression.

92. A method of preventing or treating malignant hyperthermia in a subject comprising administering to said subject a therapeutically effective amount of a compound that  
5 inhibits activation of UCP-3 in muscle tissue.

93. The method of claim 92, wherein said decrease in UCP-3 activity is associated with a decrease in UCP-3 activation.

94. The method of claim 92, wherein said decrease in  
10 UCP-3 activity is associate with a decrease in UCP-3 gene expression.

95. A method of preventing or treating fever in a subject comprising administering to said subject a therapeutically effective amount of a compound that inhibits  
15 activation of UCP-3 in muscle tissue.

96. The method of claim 95, wherein said decrease in UCP-3 activity is associated with a decrease in UCP-3 activation.

97. The method of claim 95, wherein said decrease in  
20 UCP-3 activity is associated with a decrease in UCP-3 gene expression.

98. A method for determining whether a subject has a condition or disorder related to UCP-3 expression or structure, comprising:

a) probing the nucleic acid in a tissue of said subject with a nucleotide probe that comprises a nucleotide sequence that is homologous to at least 15 consecutive nucleotides of a UCP-3 nucleotide sequence; and

5           b) determining the amount of said nucleic acid bound by said probe.

99. The method of claim 98, further comprising the step of comparing the amount of said bound nucleic acid to the amount of nucleic acid bound by said probe in a subject that  
10 does not have a condition or disorder related to UCP-3 expression or structure.

100. The method of claim 99, wherein said nucleotide probe is homologous to at least 30 consecutive nucleotides of a UCP-3 nucleotide sequence.

15           101. The method of claim 99, wherein said nucleotide probe is homologous to at least 45 consecutive nucleotides of a UCP-3 nucleotide sequence.

102. The method of claim 99, wherein said UCP-3 nucleotide sequence is a rat or a mouse UCP-3 nucleotide  
20 sequence.

103. The method of claim 99, wherein said UCP-3 nucleotide sequence is a human UCP-3 nucleotide sequence.

105. The method of claim 99, wherein the nucleotide sequence is homologous to at least 30 consecutive nucleotides of the nucleotide sequence of Figure 5.

107. A method for determining whether a subject has a condition or disorder related to UCP-3 expression or structure, comprising

b) determining whether said deletions or point mutations are associated with a condition or disorder related to UCP-3 expression or structure.

109. The method of any claims 95 and 98-107, wherein said condition or disorder is malignant hyperthermia, or a susceptibility to malignant hyperthermia.

110. A method for determining whether a subject has a condition or disorder related to a defect in the expression level of UCP-3 in a tissue of said subject comprising determining the level of UCP-3 present in said tissue.

5        111. The method of claim 110, further comprising and comparing said level of said UCP-3 with the level of UCP-3 in a subject that does not have a condition or disorder related to a defect in the expression level of UCP-3.

112. The method of claim 110, wherein said level of UCP-  
10        3 present in said tissue is determined by probing said tissue with an antibody that recognizes UCP-3.

113. The method of claim 110, wherein said antibody is a monoclonal antibody.

114. The method according to any of claims 110-113,  
15        wherein said subject is determined to have a condition or disorder related to obesity if said defect in the expression level of UCP-3 in said tissue of said subject results in a decreased level of UCP-3 as compared to a subject that does not have a condition or disorder related to obesity.

20        115. The method according to any of claims 110-113, wherein said subject is determined to have a susceptibility to malignant hyperthermia if said defect in the expression level of UCP-3 in said tissue of said subject results in an increased level of UCP-3 as compared to a subject that does  
25        not have a susceptibility to malignant hyperthermia.

Figure 1

91

GGTGACCTACGACATCCTCAAGGAGAAGCTGCTGGACTACCACTGCTCACTGACAACTTCCCTGCCACTTTGTCCTCTGCTTTGGAGCC  
V T Y D I L K E K L L D Y H L L T D N F P C H F V S A F G A

181

GGCTTCTGTGCCACAGTGGTGGCATCCCCGGTGGACGTTGTAAGACCCGGTATATGAACCTCACCTCCAGGCCAGTACTTCAGCCCCCTC  
G F C A T V V A S P V D V V K T R Y M N S P P G Q Y F S P L

271

TM 6  
GACTGTATGATAAAGATGGTGGCCAGGAGCGCCACCCAGCCTTCTACAAGGATTTTACACCCCTCCTTTTGGCGTTGGGATCCTGGAAC  
D C M I K M V A Q E A P P A F Y K G F T P S F L R L G S W N

361

GTGGTGATGTTCTGTAACCTATGAGCAGCTGAAACGGGGCCCTGATGAAAGTCCAGATGTTACGGGAATCACCGTTTGAACAAGACAAGAA  
V V M F V T Y E Q L K R A L M K V Q M L R E S P F

405

GGCCACTGGTAGCTAAAGTGTCCGAAACCAAGTTAAGAATGGAAG

Figure 2

UCP-1	1	MGGLTASDVH/	*	
UCP-3	1	NCTELVTYDLMKEAFVKNNILADDVPCHLVSAIIAGFCATAMSSPVDVVKTRF		240
		VTYDILKEKLLDYHLLTDNFPCHFVSAGAGFCATVVASPVDVVKTRY		48
UCP-1	241	INSPPGQYKSPNCAKVFVFTNEGPTAFFKGLVPSFLRLGSWNVIMFVCFEQLKRELKSRQTMDC		306
UCP-3	49	MNSPPGQYFSPDCMIKMWAEAPPFAFYKGF		114

TM 6

\* Note: amino acid residues 11 through 187 of UCP-1 are not shown.

FIG. 3B.






FIG. 3A.





4/6

FIG. 4.



5/6

AAAGGACTGGCAGAGCCTTCCAGGACT -1

ATGGTTGGACTGAAGCCTTCAGACGTGCCTCCCACCATGGCTGTGAAGTTCCTGGGGGCGAGCACAGCA 69  
1 M V G L K P S D V P P T M A V K F L G A G T A

GCCTGTTTTGCTGACCTCGTTACCTTTCCACTGGACACAGCCAAGGTCCGCCTGCAGATCCAGGGGGAG 138  
24 A C F A D L V T F P L D T A K V R L Q I Q G E

AACCAGGCGGTCCAGACGGCCCGGCTCGTGAGTACCGTGGCGTGCTGGGCACCATCCTGACCATGGTG 207  
47 N Q A V Q T A R L V Q Y R G V L G T I L T M V

CGGACTGAGGGTCCCTGCAGCCCCTACAATGGGCTGGTGGCCGGCCTGCAGCGCCAGATGAGCTTCGCC 276  
70 R T E G P C S P Y N G L V A G L Q R Q M S F A

TCCATCCGCATCGGCCTCTACGACTCCGTCAAGCAGGTGTACACCCCCAAAGGCGCGGACAACCTCCAGC 345  
93 S I R I G L Y D S V K Q V Y T P K G A D N S S

CTCACTACCCGATTTTGGCCGGCTGCACCACAGGAGCCATGGCGGTGACCTGTGCCCAGCCCACAGAT 414  
116 L T T R I L A G C T T G A M A V T C A Q P T D

GTGGTGAAGGTCCGATTTTCAGGCCAGCATAACCTCGGGCCATCCAGGAGCGACAGAAAATACAGCGGG 483  
139 V V K V R F Q A S I H L G P S R S D R K Y S G

ACTATGGACGCCTACAGAACCATCGCCAGGGAGGAAGGAGTCAGGGGCCTGTGGAAAGGAACCTTGTCCC 552  
162 T M D A Y R T I A R E E G V R G L W K G T L P

AACATCATGAGGAATGCTATCGTCAACTGTGCTGAGGTGGTGACCTACGACATCCTCAAGGAGAAGCTG 621  
185 N I M R N A I V N C A E V V T Y D I L K E K L

CTGGACTATCACCTGCTCACTGACAACCTTCCCCTGCCACTTTGTCTCTGCCTTTGGAGCCGGCTTCTGT 690  
208 L D Y H L L T D N F P C H F V S A F G A G F C

GCCACAGTGGTGGCCTCCCCTGGGACGTGGTGAAGACCCGGTATATGAACCTCACCTCCAGGCCAGTAC 759  
231 A T V V A S P V D V V K T R Y M N S P P G Q Y

TTCAGCCCCCTCGACTGTATGATAAAGATGGTGGCCAGGAGGGCCCCACAGCCTTCTACAAGGGATTT 828  
254 F S P L D C M I K M V A Q E G P T A F Y K G F

ACACCCTCCTTTTTGCGTTTGGGATCCTGGAACGTGGTGATGTTTCGTAACCTATGAGCAGCTGAAACGG 897  
277 T P S F L R L G S W N V V M F V T Y E Q L K R

GCCCTGATGAAAGTCCAGATGTTACGGGAATCACCGTTTTTGAACAAGACAAGAAGGCCACTGGTAGCTA 966  
300 A L M K V Q M L R E S P F •

ACGTGTCCGAAACCAGTTAAGAATGGAAG

Figure 5

SUBSTITUTE SHEET (RULE 26)



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/05892

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.

US CL : 435/69.1, 172.3, 243, 320.1, 325; 536/23.1, 23.5, 24.1

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/69.1, 172.3, 243, 320.1, 325; 536/23.1, 23.5, 24.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y,P	URHAMMER, S.A. et al. Organisation of the coding exons and mutational screening of the uncoupling protein 3 in subjects with juvenile-onset obesity. Diabetologia. 1998, Vol. 41, pages 241-244, see entire document.	1-13
Y,P	LIU, Q. et al. Uncoupling protein-3: a muscle-specific gene upregulated by leptin in ob/ob mice. Gene. 1998, Vol. 207, pages 1-7, see entire document.	1-13
Y,P	VIDAL-PUIG, A. et al. UCP-3: An uncoupling protein homologue expressed preferentially and abundantly in skeletal muscle and brown adipose tissue. Biochemical and Biophysical Research Communications. 1997, Vol. 235, pages 79-82, see entire document.	1-13

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

18 JUNE 1998

Date of mailing of the international search report

29 JUL 1998

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

BRIAN R. STANTON

Telephone No. (703) 308-0196

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/05892

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
1-13

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/05892

## A. CLASSIFICATION OF SUBJECT MATTER: IPC (6):

C07H 21/04; C12N 1/00, 5/00, 5/10, 15/00, 15/09, 15/11, 15/12; C12P 21/06

## B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

Databases: APS, Medline, Embase, CA, Biosis, Derwent world patents  
Search Terms: thermogen?; uncoupl?; ucp?; mitochondr?; larkin?/au; albrandt?/au; moore?/au; young?/au; beaumont?/au

## BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1.

Group I, claim(s) 1-13, drawn to nucleic acids encoding UCP-3.

Group II, claim(s) 14-17, drawn to UCP-3 proteins.

Group III, claim(s) 18-20, drawn to antibodies against UCP-3 proteins.

Group IV, claim(s) 21-28, drawn to methods of treating obesity using nucleic acids encoding UCP-3.

Group V, claim(s) 29-62, drawn to screening assays for studying UCP-3 binding.

Group VI, claim(s) 63-81, drawn to assays for detecting compounds that regulate UCP-3 expression.

Group VII, claim(s) 82-97, drawn to methods of treating obesity using compounds that affect the activity of UCP-3.

Group VIII, claim(s) 98-115, drawn to assay methods using nucleic acids to detect UCP-3 genes and expression.

The inventions listed as Groups I-VIII do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The technical feature of the invention of group I is drawn to nucleic acids that encode UCP-3. However, the prior art as represented by the teachings of Vidal-Puig et al., (1997) indicates that nucleic acids with sequences that were related to those encoding UCP proteins were known to have existed in the prior art (see e.g. page 80, first column, second paragraph). Given that UCP related nucleic acids were known in the art, nucleic acids designated simply as those encoding UCP-3 do not constitute a special technical feature with the meaning of PCT Rule 13.2 so as to link the severally claimed inventions with a single inventive concept.

The technical feature of the invention of group II is drawn to UCP-3 proteins and that of group III is antibody molecules. Neither of these two types of proteins bear any requisite structural or functional relationship with the nucleic acids of the invention of group I. Nor are such proteins required for use in the methods of groups IV or VIII.

The technical feature of the invention of group IV is the treatment of multicellular organisms using nucleic acids. Therefore, this feature relates to the interaction of a nucleic acid with a host and the effect that this interaction has on a multisite disorder such as obesity. Since nucleic acids may be used in materially different manners (such as in assays (group VIII) or for preparation of proteins, such nucleic acids do not *a priori* share the technical feature of the claimed treatment methods. Similarly, the technical feature of the invention of group VIII relates to assays of gene expression and mutations and does not *per se* relate to nucleic acids encoding normal UCP-3 proteins.

The technical feature of the invention of group V is drawn to screening assays for agents that bind to UCP-3 proteins and therefore these assays do not relate to nucleic acids, assays using such, or to any proteins or antibodies *per se*. Similarly, the technical feature of the invention of group VI is drawn to assays for compounds that regulate UCP-3 expression and that of the invention of group VII is drawn to methods of treating obesity. Therefore, these technical features do not relate to those associated with proteins, antibodies, or nucleic acids *per se*.

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/05892

The technical feature of the invention of group VII is drawn to treatment methods using agents that affect UCP-3 activity. Such methods do not utilize nucleic acids, proteins, or antibodies *per se* and do not involve methods that use these latter types of molecules.

Therefore, for the foregoing reasons, the several claimed inventions do not share any special technical feature within the meaning of PCT Rule 13.2 so as to relate to a single inventive concept under PCT Rule 13.1.

**THIS PAGE BLANK (USPTO)**

---